Chimeric small molecules for the recruitment of antibodies to cancer cells

ABSTRACT

The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.

RELATED APPLICATIONS

This application is a continuation in part application of U.S. patentapplication Ser. No. 12/991,926 of identical title filed Nov. 10, 2010,which is a United States national phase application of PCT/US2009/002957(published as WO2009/139863, filed 13 May 2009, which claims priorityfrom U.S. provisional application U.S. 61/127,539 of identical titlefiled May 13, 2008. This application also claims the benefit of priorityof U.S. provisional application no. U.S. 61/360,732, filed Jul. 1, 2010of identical title. Each of the foregoing applications is incorporatedby reference in its entirety hereof.

GRANT SUPPORT

This invention was supported by a grant from the National Institutes ofHealth, grant no. 1DP2OD002913-01. Consequently, the government retainscertain rights in the invention.

FIELD OF THE INVENTION

The present invention relates to chemical compounds which are used torecruit antibodies to cancer cells, in particular, prostate cancer cellsor metastasized prostate cancer cells. The compounds according to thepresent invention comprise an antibody binding terminus (ABT) moietycovalently bonded to a cell binding terminus (CBT) through a linker andoptionally and preferably, a connector molecule. In addition, given thatthe protein target is found on the neovasculature of most non-prostaticcancer cells, the compounds in the present invention also serves as anantiangiogenic therapy for other cancer types.

BACKGROUND OF THE INVENTION

It has been predicted that one out of every six American men willdevelop prostate cancer in their lifetime. See, American Cancer Society,Cancer Facts and Figures 2008. Atlanta: American Cancer Society; 2008.Despite recent advances in both prostate cancer detection and treatment,it remains one of the leading causes of cancer-related death among theAmerican male population.

Anti-DNP antibodies are readily present in high concentrations of thehuman bloodstream. See Ortega, E.; Kostovetzky, M.; Larralde, C. Mol.Immun. 1984, 21, 883. A number of cancer-related, antibody directingsmall molecules having been synthesized. See, Lu, et al., Adv. DrugDeliv. Rev. 2004, 56, 1161; Lu, et al., Mol. Pharmaceut. 2007, 4, 695;Carlson, et al., ACS Chem. Bio. 2007, 2, 119; and Popkov, M.; Gonzalez,B.; Sinha, S. C.; Barbas, C. F., III. Proc. Nat. Acad. Sci., 2009, 1.

The present invention is directed to the design and synthesis of a newsmall-molecule capable of redirecting endogenous anti-dinitrophenyl(DNP) antibodies selectively to prostate cancer cells, and inducingantibody-directed, cell-mediated cytotoxicity.

When prostate cancer is diagnosed prior to metastasis, the patient has agreater then 99% chance of survival. The most successful means fortreating prostate cancer at this stage is a radical prostatectomy.Unfortunately, this surgery carries with it the risk of severing nervesand blood vessels associated with sexual organs and the bladder, and canpotentially result in impotency or incontinency. Radiation therapy isyet another commonly used procedure that carries the risk of impotency.Half the patients who undergo radiation therapy for prostate cancerbecome impotent within 2 years of treatment. In addition to the adverseaffects associated with these procedures, they are significantly lesseffective in patients whose cancer has already delocalized ormetastasized on diagnosis. In these cases, patients generally undergoeven more invasive procedures such as hormonal therapy or chemotherapy.Unfortunately, most patients eventually stop responding to hormonaltherapy and the most successful chemotherapeutic, Taxotere, onlyprolongs the life of advanced prostate cancer patients by 2.5 months onaverage.

As another alternative therapeutic, monoclonal antibody (mAb)-basedimmunotherapy has proven clinically beneficial for cancer patients whileallowing them to maintain a good quality of life. These antibodies caneither regulate proliferation of cancer cells through the manipulationof signal transduction, or promote cytotoxicity. Two examples ofFDA-approved mAb-based anticancer drugs are Herceptin and Rituxan(Rituximab), which are currently being used for the treatment of breastcancer and non-Hodgkin's lymphoma, respectively. While there are nomAb-based therapeutics currently available for prostate cancer patients,advanced clinical studies on mAb-based immunotherapy has shown promisefor the treatment of prostate cancer including advanced prostate cancer.Despite the major advantages of mAb-based immunotherapy, there aresignificant pitfalls which may limit its potential. In general,mAb-based therapeutics are highly costly ($70,000 for full course oftreatment of Herceptin), lack oral bioavailability, and can lead tosevere and often fatal side-effects. For example, Herceptin isassociated with heart problems and cannot be administered toapproximately 10% of cancer patients because of heart-relatedcomplications. Rituxan can cause several side-effects which includerenal failure, infections and immune and pulmonary toxicity.

Although still in its infancy, the concept of using small molecules totemplate the human immune response has shown realistic potential. Recentreports have surfaced in which small molecules have been used to directantibodies to cancerous cells such as breast carcinoma cells, melanomacells, and nasopharyngeal epidermal carcinoma cells. Animal studies havedemonstrated that these molecules can promote tumor rejection andantitumor immunity in mice. Because this process allows for thedirection of endogenous antibodies selectively to the cell of interest,it has the potential to harness the power of mAb-based therapeuticswhile limiting the costs and side effects associated with administeringexogenous antibodies. By developing similar methods which recruitanti-DNP antibodies to prostate cancer cells, the proposed research willhelp broaden this field while creating a new therapy for all forms ofprostate cancer.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows scheme 1, which is a schematic depiction of small-moleculetemplated immunotherapy.

FIG. 2(A) shows computational modeling of cell-binding terminus in thebinding pocket of PSMA. FIG. 2(B) shows a model of PSMA-smallmolecule-Anti-DNP antibody ternary complex.

FIG. 3 shows a prostate cancer antibody-recruiting molecule of thepresent invention, PC-ARM (3).

FIG. 4 shows the synthesis of the prostate cancer antibody-recruitingmolecule of FIG. 3. The azide-functionalized cell-binding terminus wassynthesized in 3 steps by coupling Cbz-protected lysine and t-butylprotected glutamic acid with triphosgene, followed by Cbz deprotectionand azide formation (scheme 2). Heterobifunctional PEG 10 wassynthesized in a five step process from octaethylene glycol (scheme 2).These intermediates were coupled via microwave assisted,copper-catalyzed Huisgen cyloaddition, and deprotected using microwaveassisted TFA deprotection (scheme 3) afforded the prostate cancerantibody-recruiting molecule of the present invention PC-ARM (3).

FIG. 5 shows in (A) a representative flow cytometry histogramillustrating small-molecule 3-dependant anti-DNP antibody binding toPSMA-expressing LNCaP cells. LNCaP cells were preincubated with 3 (50nM), and subsequently incubated with Alexa Fluor 488-conjugated anti-DNPantibodies. (B) Representative flow cytometry histogram illustrating nosmall-molecule 3 dependant anti-DNP antibody binding to PSMA-negativeDU-145 cells. DU-145 cells were preincubated with 3 (50 nM), andsubsequently incubated with Alexa Fluor 488-conjugated anti-DNPantibodies.

FIG. 6 shows the change in % cell killing induced by PC-ARM (3) (shownin the figure as P-ARM8). In short, LNCaP cells and PBMCs were incubatedin the presence of anti-DNP antibody IgG1, IgG3 and a sample of normalhuman IgG known to have anti-DNP antibodies for 24 hours at 37° C. Thechange in % cell-killing reflects the increase associated with additionof 50 nM P-ARM8 (3). The data was run in dodecaplets, and is reported asthe average±SEM. In addition, each experiment was run in parallel with50 nM P-ARM8 alone to screen for inherent small-molecule inducedcell-killing.

FIG. 7 shows exemplary compounds according to the present invention.

FIG. 8 shows additional exemplary compounds according to the presentinvention.

FIG. 9 shows divergent synthetic scheme 1a which is used for targetsynthesis.

FIG. 10 shows Scheme 2a—synthesis toward propargyl intermediates used insynthesizing compounds according to the invention.

FIG. 11 shows Scheme 3a which is directed to the synthesis ofintermediate 15, and proposed access to azide intermediate 16 to be usedin click chemistry.

FIG. 12 shows scheme 4a which describes a synthetic approach to bisdi-DNP lysine 21.

FIG. 13 shows scheme 5a which describes a synthetic approach to thetris-azidylated analog which can be used to condense with the bis-diDNPlysine 21 to produce compound 3 of FIG. 8 or similar compounds.

FIG. 14 shows the structure and function of ARM-Ps (antibody-recruitingmolecules targeting prostate cancer). (A) ARM-Ps recruit anti-DNPantibodies to PSMA-expressing prostate cancer cells, and thereby bringabout immune-mediated cytotoxicity. (B) ARM-Ps are bifunctional andconsist of an antibody-binding terminus (ABT), a linker region, and acell-binding terminus (CBT).

FIG. 15 shows the correlation between K_(i) values and EHOMO of aromaticring component of ARM-P analogues. Measured Ki values (mean oftriplicate experiments±standard deviation) are plotted versus HOMOenergies calculated using density functional theory (DFT). The hybridfunctional B3LYP with a 6-31G*+basis set was used.

FIG. 16 provides a close-up of PSMA active site bound to bifunctionalglutamate urea inhibitors ARM-P2 (gold), ARM-P4 (grey), and ARM-P8(blue). Structures were superimposed on with corresponding (orequivalent) Cα atoms. Inhibitors are shown in stick representation andprotein residues are shown as lines. Hydrogen bonding interactions areindicated by dashed lines. The zinc ions and chloride ion in the activesite are labeled as grey and green dotted spheres, respectively, andwater molecules are depicted as red spheres. In both protein andinhibitor structures, carbon atoms are colored as indicated above, andother atoms are colored red (oxygen), and blue (nitrogen).

FIG. 17 shows that the PSMA/ARM-P2 complex reveals a previouslyunreported arene-binding cleft. (A) Global view of PSMA with a close-upof arene-binding site. Residues making up the arene-binding cleft arelabeled in cyan. The entrance lid (residues 542-548), which resides inan open conformation in the ARM-P2 complex, is indicated as a red loop.Overlaid on this complex is the entrance lid in its closed conformation(colored blue), which would come into steric conflict with the linkerregion of the inhibitor. (B and C) Close-up images of the urea bindingsites in structures containing both open and closed entrance loops. Inall panels, structural data for PSMA with a the closed entrance lidcomes from the complex with the small urea-based inhibitor DCIBzL (PDBID-3IWW).30 The zinc ions in the active site are labeled as orangespheres and the ARM-P2 carbons are colored gold. The DCIBzL carbons in Band C are colored purple.

FIG. 18 provides a close-up view of the active site of PSMA bound toMeO-P4. Hydrogen bonding interactions are indicated by dashed lines. Thezinc ions in the active site and adjacent chloride ion are labeled asgrey and green dotted spheres, respectively, and water molecules aredepicted as red/darker spheres. In both protein and inhibitorstructures, carbon atoms are colored in olive, and other atoms arecolored red (oxygen), and blue (nitrogen).

FIG. 19 provides selected snapshots from the MD simulations ofPSMA/ARM-P complexes. The ligands are represented in varying shadedsticks, Arg463, Arg511 and Trp541 are represented in lighter graysticks. Figure created with the program VMD.³⁷

OBJECTS OF THE INVENTION

It is an object of the invention to provide chimeric compounds which canbe used to treat virtually any cancer, especially including prostatecancer and metastatic prostate cancer.

It is an additional object of the invention to provide chimericcompounds which can be used to provide pharmaceutical compositions,including pharmaceutical compositions which include additional bioactiveagents or agents which assist in the treatment of cancer, especiallyprostate cancer, including metastatic prostate cancer.

It is still another object of the invention to provide methods fortreating cancer, including prostate cancer, including metastaticprostate cancer.

Yet a further object of the invention is to provide methods forinhibiting metastatis of cancer, especially including metastaticprostate cancer.

These and/or other objects of the invention may be readily gleaned froma review of the invention as described herein.

BRIEF DESCRIPTION OF THE INVENTION

It is an aspect of the invention to provide chimeric antibody recruitingmolecules which bind to prostate specific membrane antigen (PMSA) andattract antibodies such that the chimeric molecules will assist inimmunotherapy of a patient with virtually any cancer, especiallyincluding prostate cancer, and further including metastatic prostatecancer.

In this first aspect of the invention, chimeric antibody recruitingmolecules are represented by the formula:

Wherein A is an antibody binding moiety comprising a hapten which iscapable of binding to an antibody in a patient;B is a cell binding moiety capable of binding to prostate specificmembrane antigen on the cell surface of cells in said patient;L is a linker molecule which links [CON] to A or B in a molecule;[CON] is a bond or a connector molecule linking said linker molecule toA or B; andEach n in a molecule is independently an integer from 1 to 15, 1 to 10,1 to 5, 1 to 3, 2 to 3, 2 to 5,Or a pharmaceutically acceptable salt, solvate or polymorph thereof.

In an additional aspect of the invention, a pharmaceutical compositioncomprises an effective amount of a chimeric compound as described above,optionally and preferably in combination with a pharmaceuticallyacceptable carrier, additive or excipient. In alternative aspects,pharmaceutical combination compositions comprise an effective amount ofa chimeric compound as described herein, in combination with at leastone additional agent which is used to treat cancer, including prostatecancer, especially including metastatic prostate cancer or a secondarycondition or effect of cancer, especially prostate cancer (e.g., bonepain, hyperplasia, osteoporosis, etc. as otherwise described herein).

In a further aspect of the invention, compounds according to the presentinvention are used to treat cancer in a patient, especially prostatecancer in male patients in need thereof. The method of treating cancercomprises administering to a patient in need an effective amount of achimeric compound as otherwise described herein in combination with apharmaceutically acceptable carrier, additive or excipient, optionallyin further combination with at least one additional agent which iseffective in treating cancer, especially including prostate cancer,metastatic cancer or one or more of its secondary conditions or effects.

The present invention also relates to a method for inhibiting prostatecancer to reduce or inhibit the spread or metastasis of the cancer intoother tissues of the patients' body, especially including bones, thelymph (lymph nodes) system, bladder, vas deferens, kidneys, liver, lungsand brain, among others.

The present invention also relates to instances in which destruction ofnon-cancerous cells which possess PSMA can be of therapeutic use,especially in cancer therapy. For example, given that PSMA is found onthe neovasculare of many non-prostatic cancer cells, but not on normalvasculature, the invention could be used for antiangiogenic therapy forother forms of cancer by targeting the neovasculature of those cancers.

DETAILED DESCRIPTION OF THE INVENTION

The following terms are used to describe the present invention. Ininstances where a term is not specifically defined herein, that term isgiven an art-recognized meaning by those of ordinary skill applying thatterm in context to its use in describing the present invention.

The term “compound”, as used herein, unless otherwise indicated, refersto any specific chemical compound disclosed herein and includestautomers, regioisomers, geometric isomers, and where applicable,optical isomers (enantiomers) thereof, as well as pharmaceuticallyacceptable salts and derivatives (including prodrug forms) thereof.Within its use in context, the term compound generally refers to asingle compound, but also may include other compounds such asstereoisomers, regioisomers and/or optical isomers (including racemicmixtures) as well as specific enantiomers or enantiomerically enrichedmixtures of disclosed compounds. The term also refers, in context toprodrug forms of compounds which have been modified to facilitate theadministration and delivery of compounds to a site of activity. It isnoted that in describing the present compounds, numerous substituents,linkers and connector molecules and variables associated with same,among others, are described. It is understood by those of ordinary skillthat molecules which are described herein are stable compounds asgenerally described hereunder.

The term “patient” or “subject” is used throughout the specificationwithin context to describe an animal, generally a mammal and preferablya human, to whom treatment, including prophylactic treatment(prophylaxis), with the compositions according to the present inventionis provided. For treatment of those infections, conditions or diseasestates which are specific for a specific animal such as a human patientor a patient of a particular gender, such as a human male patient, theterm patient refers to that specific animal. Compounds according to thepresent invention are useful for the treatment of cancer, especiallyincluding prostate cancer and in particular, metastatic prostate cancer.

The term “effective” is used herein, unless otherwise indicated, todescribe an amount of a compound or composition which, in context, isused to produce or effect an intended result, whether that resultrelates to the inhibition of the effects of a toxicant on a subject orthe treatment of a subject for secondary conditions, disease states ormanifestations of exposure to toxicants as otherwise described herein.This term subsumes all other effective amount or effective concentrationterms (including the term “therapeutically effective”) which areotherwise described in the present application.

The terms “treat”, “treating”, and “treatment”, etc., as used herein,refer to any action providing a benefit to a patient at risk forprostate cancer or metastasis of prostate cancer, including improvementin the condition through lessening or suppression of at least onesymptom, inhibition of cancer growth, reduction in cancer cells ortissue, prevention or delay in progression of metastasis of the cancer,prevention or delay in the onset of disease states or conditions whichoccur secondary to cancer or remission or cure of the cancer, amongothers. Treatment, as used herein, encompasses both prophylactic andtherapeutic treatment. The term “prophylactic” when used, means toreduce the likelihood of an occurrence or the severity of an occurrencewithin the context of the treatment of cancer, including cancermetastasis as otherwise described hereinabove.

The term “neoplasia” or “cancer” is used throughout the specification torefer to the pathological process that results in the formation andgrowth of a cancerous or malignant neoplasm, i.e., abnormal tissue thatgrows by cellular proliferation, often more rapidly than normal andcontinues to grow after the stimuli that initiated the new growth cease.Malignant neoplasms show partial or complete lack of structuralorganization and functional coordination with the normal tissue and mostinvade surrounding tissues, metastasize to several sites, and are likelyto recur after attempted removal and to cause the death of the patientunless adequately treated. As used herein, the term neoplasia is used todescribe all cancerous disease states and embraces or encompasses thepathological process associated with malignant hematogenous, ascitic andsolid tumors. Representative cancers include, for example, prostatecancer, metastatic prostate cancer, stomach, colon, rectal, liver,pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, testis,bladder, renal, brain/CNS, head and neck, throat, Hodgkin's disease,non-Hodgkin's lymphoma, multiple myeloma, leukemia, melanoma,non-melanoma skin cancer, acute lymphocytic leukemia, acute myelogenousleukemia, Ewing's sarcoma, small cell lung cancer, choriocarcinoma,rhabdomyosarcoma, Wilms' tumor, neuroblastoma, hairy cell leukemia,mouth/pharynx, oesophagus, larynx, kidney cancer and lymphoma, amongothers, which may be treated by one or more compounds according to thepresent invention. Because of the activity of the present compounds asanti-angiogenic compounds, the present invention has generalapplicability treating virtually any cancer in any tissue, thus thecompounds, compositions and methods of the present invention aregenerally applicable to the treatment of cancer. Given that the proteintarget is found on the neovasculature of most non-prostatic cancercells, the compounds in the present invention may also serve as anantiangiogenic therapy for other cancer types.

In certain particular aspects of the present invention, the cancer whichis treated is prostate cancer or metastatic prostate cancer. Separately,metastatic prostate cancer may be found in virtually all tissues of acancer patient in late stages of the disease, typically metastaticprostate cancer is found in seminal vesicles, lymph system/nodes(lymphoma), in bones, in bladder tissue, in kidney tissue, liver tissueand in virtually any tissue, including brain (brain cancer/tumor). Thus,the present invention is generally applicable and may be used to treatany cancer in any tissue, regardless of etiology.

The term “prostate cancer” is used to describe a disease in which cancerdevelops in the prostate, a gland in the male reproductive system. Itoccurs when cells of the prostate mutate and begin to multiplyuncontrollably. These cells may metastasize (metastatic prostate cancer)from the prostate to virtually any other part of the body, particularlythe bones and lymph nodes, but the kidney, bladder and even the brain,among other tissues. Prostate cancer may cause pain, difficulty inurinating, problems during sexual intercourse, erectile dysfunction.Other symptoms can potentially develop during later stages of thedisease.

Rates of detection of prostate cancers vary widely across the world,with South and East Asia detecting less frequently than in Europe, andespecially the United States. Prostate cancer develops most frequentlyin men over the age of fifty and is one of the most prevalent types ofcancer in men. However, many men who develop prostate cancer never havesymptoms, undergo no therapy, and eventually die of other causes. Thisis because cancer of the prostate is, in most cases, slow-growing, andbecause most of those affected are over the age of 60. Hence, they oftendie of causes unrelated to the prostate cancer. Many factors, includinggenetics and diet, have been implicated in the development of prostatecancer. The presence of prostate cancer may be indicated by symptoms,physical examination, prostate specific antigen (PSA), or biopsy. Thereis concern about the accuracy of the PSA test and its usefulness inscreening. Suspected prostate cancer is typically confirmed by taking abiopsy of the prostate and examining it under a microscope. Furthertests, such as CT scans and bone scans, may be performed to determinewhether prostate cancer has spread.

Treatment options for prostate cancer with intent to cure are primarilysurgery and radiation therapy. Other treatments such as hormonaltherapy, chemotherapy, proton therapy, cryosurgery, high intensityfocused ultrasound (HIFU) also exist depending on the clinical scenarioand desired outcome.

The age and underlying health of the man, the extent of metastasis,appearance under the microscope, and response of the cancer to initialtreatment are important in determining the outcome of the disease. Thedecision whether or not to treat localized prostate cancer (a tumor thatis contained within the prostate) with curative intent is a patienttrade-off between the expected beneficial and harmful effects in termsof patient survival and quality of life.

An important part of evaluating prostate cancer is determining thestage, or how far the cancer has spread. Knowing the stage helps defineprognosis and is useful when selecting therapies. The most common systemis the four-stage TNM system (abbreviated from Tumor/Nodes/Metastases).Its components include the size of the tumor, the number of involvedlymph nodes, and the presence of any other metastases.

The most important distinction made by any staging system is whether ornot the cancer is still confined to the prostate or is metastatic. Inthe TNM system, clinical T1 and T2 cancers are found only in theprostate, while T3 and T4 cancers have spread elsewhere and metastasizedinto other tissue. Several tests can be used to look for evidence ofspread. These include computed tomography to evaluate spread within thepelvis, bone scans to look for spread to the bones, and endorectal coilmagnetic resonance imaging to closely evaluate the prostatic capsule andthe seminal vesicles. Bone scans often reveal osteoblastic appearancedue to increased bone density in the areas of bone metastasis—oppositeto what is found in many other cancers that metastasize. Computedtomography (CT) and magnetic resonance imaging (MRI) currently do notadd any significant information in the assessment of possible lymph nodemetastases in patients with prostate cancer according to ameta-analysis.

Prostate cancer is relatively easy to treat if found early. After aprostate biopsy, a pathologist looks at the samples under a microscope.If cancer is present, the pathologist reports the grade of the tumor.The grade tells how much the tumor tissue differs from normal prostatetissue and suggests how fast the tumor is likely to grow. The Gleasonsystem is used to grade prostate tumors from 2 to 10, where a Gleasonscore of 10 indicates the most abnormalities. The pathologist assigns anumber from 1 to 5 for the most common pattern observed under themicroscope, then does the same for the second most common pattern. Thesum of these two numbers is the Gleason score. The Whitmore-Jewett stageis another method sometimes used. Proper grading of the tumor iscritical, since the grade of the tumor is one of the major factors usedto determine the treatment recommendation.

Early prostate cancer usually causes no symptoms. Often it is diagnosedduring the workup for an elevated PSA noticed during a routine checkup.Sometimes, however, prostate cancer does cause symptoms, often similarto those of diseases such as benign prostatic hypertrophy. These includefrequent urination, increased urination at night, difficulty startingand maintaining a steady stream of urine, blood in the urine, andpainful urination. Prostate cancer is associated with urinarydysfunction as the prostate gland surrounds the prostatic urethra.Changes within the gland therefore directly affect urinary function.Because the vas deferens deposits seminal fluid into the prostaticurethra, and secretions from the prostate gland itself are included insemen content, prostate cancer may also cause problems with sexualfunction and performance, such as difficulty achieving erection orpainful ejaculation.

Advanced prostate cancer can spread to other parts of the body and thismay cause additional symptoms. The most common symptom is bone pain,often in the vertebrae (bones of the spine), pelvis or ribs. Spread ofcancer into other bones such as the femur is usually to the proximalpart of the bone. Prostate cancer in the spine can also compress thespinal cord, causing leg weakness and urinary and fecal incontinence.

The specific causes of prostate cancer remain unknown. A man's risk ofdeveloping prostate cancer is related to his age, genetics, race, diet,lifestyle, medications, and other factors. The primary risk factor isage. Prostate cancer is uncommon in men less than 45, but becomes morecommon with advancing age. The average age at the time of diagnosis is70. However, many men never know they have prostate cancer.

A man's genetic background contributes to his risk of developingprostate cancer. This is suggested by an increased incidence of prostatecancer found in certain racial groups, in identical twins of men withprostate cancer, and in men with certain genes. Men who have a brotheror father with prostate cancer have twice the usual risk of developingprostate cancer. Studies of twins in Scandinavia suggest that fortypercent of prostate cancer risk can be explained by inherited factors.However, no single gene is responsible for prostate cancer; manydifferent genes have been implicated. Two genes (BRCA1 and BRCA2) thatare important risk factors for ovarian cancer and breast cancer in womenhave also been implicated in prostate cancer.

Dietary amounts of certain foods, vitamins, and minerals can contributeto prostate cancer risk. Dietary factors that may increase prostatecancer risk include low intake of vitamin E, the mineral selenium, greentea and vitamin D. A large study has implicated dairy, specificallylow-fat milk and other dairy products to which vitamin A palmitate hasbeen added. This form of synthetic vitamin A has been linked to prostatecancer because it reacts with zinc and protein to form an unabsorbablecomplex. Prostate cancer has also been linked to the inclusion of bovinesomatotropin hormone in certain dairy products.

There are also some links between prostate cancer and medications,medical procedures, and medical conditions. Daily use ofanti-inflammatory medicines such as aspirin, ibuprofen, or naproxen maydecrease prostate cancer risk. Use of the cholesterol-lowering drugsknown as the statins may also decrease prostate cancer risk. Infectionor inflammation of the prostate (prostatitis) may increase the chancefor prostate cancer, and infection with the sexually transmittedinfections chlamydia, gonorrhea, or syphilis seems to increase risk.Obesity and elevated blood levels of testosterone may increase the riskfor prostate cancer.

Prostate cancer is classified as an adenocarcinoma, or glandular cancer,that begins when normal semen-secreting prostate gland cells mutate intocancer cells. The region of prostate gland where the adenocarcinoma ismost common is the peripheral zone. Initially, small clumps of cancercells remain confined to otherwise normal prostate glands, a conditionknown as carcinoma in situ or prostatic intraepithelial neoplasia (PIN).Although there is no proof that PIN is a cancer precursor, it is closelyassociated with cancer. Over time these cancer cells begin to multiplyand spread to the surrounding prostate tissue (the stroma) forming atumor. Eventually, the tumor may grow large enough to invade nearbyorgans such as the seminal vesicles or the rectum, or the tumor cellsmay develop the ability to travel in the bloodstream and lymphaticsystem. Prostate cancer is considered a malignant tumor because it is amass of cells which can invade other parts of the body. This invasion ofother organs is called metastasis. Prostate cancer most commonlymetastasizes to the bones, lymph nodes, rectum, and bladder.

In prostate cancer, the regular glands of the normal prostate arereplaced by irregular glands and clumps of cells. When a man hassymptoms of prostate cancer, or a screening test indicates an increasedrisk for cancer, more invasive evaluation is offered. The only testwhich can fully confirm the diagnosis of prostate cancer is a biopsy,the removal of small pieces of the prostate for microscopic examination.However, prior to a biopsy, several other tools may be used to gathermore information about the prostate and the urinary tract. Cystoscopyshows the urinary tract from inside the bladder, using a thin, flexiblecamera tube inserted down the urethra. Transrectal ultrasonographycreates a picture of the prostate using sound waves from a probe in therectum.

After biopsy, the tissue samples are then examined under a microscope todetermine whether cancer cells are present, and to evaluate themicroscopic features (or Gleason score) of any cancer found. Inaddition, tissue samples may be stained for the presence of PSA andother tumor markers in order to determine the origin of maligant cellsthat have metastasized. A number of other potential approaches fordiagnosis of prostate cancer are ongoing such as early prostate cancerantigen-2 (EPCA-2), and prostasome analysis.

In addition to therapy using the compounds according to the presentinvention, therapy (including prophylactic therapy) for prostate cancersupports roles in reducing prostate cancer for dietary selenium, vitaminE, lycopene, soy foods, vitamin D, green tea, omega-3 fatty acids andphytoestrogens. The selective estrogen receptor modulator drugtoremifene has shown promise in early trials. Two medications whichblock the conversion of testosterone to dihydrotestosterone (and reducethe tendency toward cell growth), finasteride and dutasteride, are shownto be useful. The phytochemicals indole-3-carbinol and diindolylmethane,found in cruciferous vegetables (califlower and broccholi), havefavorable antiandrogenic and immune modulating properties. Prostatecancer risk is decreased in a vegetarian diet.

Treatment for prostate cancer may involve active surveillance, surgery(prostatecomy or orchiectomy), radiation therapy including brachytherapy(prostate brachytherapy) and external beam radiation as well as hormonaltherapy. There are several forms of hormonal therapy which include thefollowing, each of which may be combined with compounds according to thepresent invention.

-   -   Antiandrogens such as flutamide, bicalutamide, nilutamide, and        cyproterone acetate which directly block the actions of        testosterone and DHT within prostate cancer cells.    -   Medications such as ketoconazole and aminoglutethimide which        block the production of adrenal androgens such as DHEA. These        medications are generally used only in combination with other        methods that can block the 95% of androgens made by the        testicles. These combined methods are called total androgen        blockade (TAB), which can also be achieved using antiandrogens.    -   GnRH modulators, including agonists and antagonists. GnRH        antagonists suppress the production of LH directly, while GnRH        agonists suppress LH through the process of downregulation after        an initial stimulation effect. Abarelix is an example of a GnRH        antagonist, while the GnRH agonists include leuprolide,        goserelin, triptorelin, and buserelin.    -   The use of abiraterone acetate can be used to reduce PSA levels        and tumor sizes in aggressive end-stage prostate cancer for as        high as 70% of patients. Sorafenib may also be used to treat        metastatic prostate cancer.

Each treatment described above has disadvantages which limit its use incertain circumstances. GnRH agonists eventually cause the same sideeffects as orchiectomy but may cause worse symptoms at the beginning oftreatment. When GnRH agonists are first used, testosterone surges canlead to increased bone pain from metastatic cancer, so antiandrogens orabarelix are often added to blunt these side effects. Estrogens are notcommonly used because they increase the risk for cardiovascular diseaseand blood clots. The antiandrogens do not generally cause impotence andusually cause less loss of bone and muscle mass. Ketoconazole can causeliver damage with prolonged use, and aminoglutethimide can cause skinrashes.

Palliative care for advanced stage prostate cancer focuses on extendinglife and relieving the symptoms of metastatic disease. As noted above,abiraterone acetate shows some promise in treating advance stageprostate cancer as does sorafenib. Chemotherapy may be offered to slowdisease progression and postpone symptoms. The most commonly usedregimen combines the chemotherapeutic drug docetaxel with acorticosteroid such as prednisone. Bisphosphonates such as zoledronicacid have been shown to delay skeletal complications such as fracturesor the need for radiation therapy in patients with hormone-refractorymetastatic prostate cancer. Alpharadin may be used to target bonemetastasis. The phase II testing shows prolonged patient survival times,reduced pain and improved quality of life.

Bone pain due to metastatic disease is treated with opioid painrelievers such as morphine and oxycodone. External beam radiationtherapy directed at bone metastases may provide pain relief. Injectionsof certain radioisotopes, such as strontium-89, phosphorus-32, orsamarium-153, also target bone metastases and may help relieve pain.

As an alternative to active surveillance or definitive treatments,alternative therapies may also be used for the management of prostatecancer. PSA has been shown to be lowered in men with apparent localizedprostate cancer using a vegan diet (fish allowed), regular exercise, andstress reduction. Many other single agents have been shown to reducePSA, slow PSA doubling times, or have similar effects on secondarymarkers in men with localized cancer in short term trials, such aspomegranate juice or genistein, an isoflavone found in various legumes.

Manifestations or secondary conditions or effects of metastatic andadvanced prostate cancer may include anemia, bone marrow suppression,weight loss, pathologic fractures, spinal cord compression, pain,hematuria, ureteral and/or bladder outlet obstruction, urinaryretention, chronic renal failure, urinary incontinence, and symptomsrelated to bony or soft-tissue metastases, among others.

Additional prostate drugs which can be used in combination with thechimeric antibody recruiting compounds according to the presentinvention include, for example, the enlarged prostate drugs/agents, aswell as eulexin, flutamide, goserelin, leuprolide, lupron, nilandron,nilutamide, zoladex and mixtures thereof. Enlarged prostate drugs/agentsas above, include for example, ambenzyl, ambophen, amgenal, atrosept,bromanyl, bromodiphenhydramine-codeine, bromotuss-codeine, cardura,chlorpheniramine-hydrocodone, ciclopirox, clotrimazole-betamethasone,dolsed, dutasteride, finasteride, flomax, gecil, hexylol, lamisil,lanased, loprox, lotrisone, methenamine, methen-bella-meth Bl-phen sal,meth-hyos-atrp-M blue-BA-phsal, MHP-A, mybanil, prosed/DS, Ro-Sed, S-TForte, tamsulosin, terbinafine, trac, tussionex, ty-methate, uramine,uratin, uretron, uridon, uro-ves, urstat, usept and mixtures thereof.

The term “tumor” is used to describe a malignant or benign growth ortumefacent.

The term “antibody binding terminal moiety”, “antibody binding terminus”or “antibody binding moiety” is use to described that portion of achimeric compound according to the present invention which comprises atleast one small molecule or hapten. The term “hapten” is used todescribe a small-molecular-weight inorganic or organic molecule thatalone is not antigenic but which when linked to another molecule, suchas a carrier protein (albumin, etc.) or in the case of the presentinvention, a cell binding terminal moiety of the present compounds isantigenic; and an antibody raised against the hapten (generally, thehapten bonded or complexed to the carrier) will react with the haptenalone.

It is preferred that the antibody binding terminal comprise a haptenwhich is reactive (binds to) an endogenous antibody that pre-exists inthe patient prior to initialing therapy with the compounds of thepresent invention and does not have to be separately raised as part of atreatment regimen. Thus, haptens which comprise a di- or trinitro phenylgroup as depicted below, or a digalactose hapten (Gal-Gal-Z, preferablyGal-Gal-sugar, preferably Gal-Gal-Glu), are preferred. Additionally, acompound according to the general structure:

Where X″ is O, CH₂, NR¹, S; andR¹ is H, a C₁-C₃ alkyl group or a —C(O)(C₁-C₃) group;May be used as haptens in the present invention.

Further, a moiety according to the chemical structure:

Where X^(b) is a bond, O, CH₂, NR¹ or S may also be used as a hapten(ABT) in the present invention.

The preferred di- or trinitro phenyl hapten (ABT) moiety for use in thepresent invention may be represented by the following formula:

Where Y′ is H or NO₂;X is O, CH₂, NR¹, S(O), S(O)₂, —S(O)₂O, —OS(O)₂, or OS(O)₂O;R¹ is H, a C₁-C₃ alkyl group, or a —C(O)(C₁-C₃) group; In alternativeembodiments, in the above dinitrosubstituted phenyl ABT moiety, one ofthe above nitro groups (at the para or ortho position) may be replacedwith a hydrogen group H to provide a mononitrosubstituted phenyl ABTmoiety.

The (Gal-Gal-Z) hapten is represented by the chemical formula:

Where X′ is CH₂, O, N—R¹, or S, preferably O;R^(1′) is H or C₁-C₃ alkyl;Where Z is a bond, a monosaccharide, disaccharide, oligosaccharide,glycoprotein or glycolipid, preferably a sugar group, more preferably asugar group selected from the monosaccharides, including aldoses andketoses, and disaccharides, including those disaccharides describedherein. Monosaccharide aldoses include monosaccharides such asaldotriose (D-glyceraldehdye, among others), aldotetroses (D-erythroseand D-Threose, among others), aldopentoses, (D-ribose, D-arabinose,D-xylose, D-lyxose, among others), aldohexoses (D-allose, D-altrose,D-Glucose, D-Mannose, D-gulose, D-idose, D-galactose and D-Talose, amongothers), and the monosaccharide ketoses include monosaccharides such asketotriose (dihydroxyacetone, among others), ketotetrose (D-erythrulose,among others), ketopentose (D-ribulose and D-xylulose, among others),ketohexoses (D-Psicone, D-Fructose, D-Sorbose, D-Tagatose, amongothers), aminosugars, including galactoseamine, sialic acid,N-acetylglucosamine, among others and sulfosugars, includingsulfoquinovose, among others. Exemplary disaccharides which find use inthe present invention include sucrose (which may have the glucoseoptionally N-acetylated), lactose (which may have the galactose and/orthe glucose optionally N-acetylated), maltose (which may have one orboth of the glucose residues optionally N-acetylated), trehalose (whichmay have one or both of the glucose residues optionally N-acetylated),cellobiose (which may have one or both of the glucose residuesoptionally N-acetylated), kojibiose (which may have one or both of theglucose residues optionally N-acetylated), nigerose (which may have oneor both of the glucose residues optionally N-acetylated), isomaltose(which may have one or both of the glucose residues optionallyN-acetylated), β,β-trehalose (which may have one or both of the glucoseresidues optionally N-acetylated), sophorose (which may have one or bothof the glucose residues optionally N-acetylated), laminaribiose (whichmay have one or both of the glucose residues optionally N-acetylated),gentiobiose (which may have one or both of the glucose residuesoptionally N-acetylated), turanose (which may have the glucose residueoptionally N-acetylated), maltulose (which may have the glucose residueoptionally N-acetylated), palatinose (which may have the glucose residueoptionally N-acetylated), gentiobiluose (which may have the glucoseresidue optionally N-acetylated), mannobiose, melibiose (which may havethe glucose residue and/or the galactose residue optionallyN-acetylated), melibiulose (which may have the galactose residueoptionally N-acetylated), rutinose, (which may have the glucose residueoptionally N-acetylated), rutinulose and xylobiose, among others.Oligosaccharides for use in the present invention as Z can include anysugar of three or more (up to about 100) individual sugar (saccharide)units as described above (i.e., any one or more saccharide unitsdescribed above, in any order, especially including glucose and/orgalactose units as set forth above), or for example,fructo-oligosaccharides, galactooligosaccharides andmannan-oligosaccharides ranging from three to about ten-fifteen sugarunits in size. Glycoproteins for use in the present invention include,for example, N-glycosylated and O-glycosylated glycoproteins, includingthe mucins, collagens, transferring, ceruloplasmin, majorhistocompatability complex proteins (MHC), enzymes, lectins andselectins, calnexin, calreticulin, and integrin glycoprotein IIb/IIa,among others. Glycolipids for use in the present invention include, forexample, glyceroglycolipids (galactolipids, sulfolipids),glycosphingolipids, such as cerebrosides, galactocerebrosides,glucocerebrosides (including glucobicaranateoets), gangliosides,globosides, sulfatides, glycophosphphingolipids and glycocalyx, amongothers.

Preferably, Z is a bond (linking a Gal-Gal disaccharide to a linker orconnector molecule) or a glucose or glucosamine (especiallyN-acetylglucosamine). It is noted that Z is linked to a galactoseresidue through a hydroxyl group or an amine group on the galactose ofGal-Gal, preferably a hydroxyl group. A preferred hapten is Gal-Gal-Gluwhich is represented by the structure:

The term “cell binding terminal moiety”, “cell binding terminus” or“cell binding moiety” is use to described that portion of a chimericcompound according to the present invention which comprises at least onesmall molecule or moiety which can bind specifically to prostatespecific membrane antigen (PSMA).

Preferred CBT groups for use in the present invention are set forthbelow:

Where X₁ and X₂ are each independently CH₂, O, NH or S;X₃ is O, CH₂, NR¹, S(O), S(O)₂, —S(O)₂O, —OS(O)₂, or OS(O)₂O;R¹ is H, a C₁-C₃ alkyl group, or a —C(O)(C₁-C₃) group;k is an integer from 0 to 20, 8 to 12, 1 to 15, 1 to 10, 1 to 8, 1 to 6,1, 2, 3, 4, 5 or 6;or a salt thereof.

The term “linker” refers to a chemical entity connecting an antibodybinding terminus (ABT) moiety to a cell binding terminus (CBT) moiety,optionally through a connector moiety through covalent bonds. The linkerbetween the two active portions of the molecule, that is the antibodybinding terminus (ABT) and the cell binding terminus (CBT) ranges fromabout 5 Å to about 50 Å or more in length, about 6 Å to about 45 Å inlength, about 7 Å to about 40 Å in length, about 8 Å to about 35 Å inlength, about 9 Å to about 30 Å in length, about 10 Å to about 25 Å inlength, about 7 Å to about 20 Å in length, about 5 Å to about 16 Å inlength, about 5 Å to about 15 Å in length, about 6 Å to about 14 Å inlength, about 10 Å to about 20 Å in length, about 11 Å to about 25 Å inlength, etc. Linkers which are based upon ethylene glycol units and arebetween 8 and 12 glycol units in length may be preferred. By having alinker with a length as otherwise disclosed herein, the ABT moiety andthe CBT moiety may be situated to advantageously take advantage of thebiological activity of compounds according to the present inventionwhich bind to prostate specific membrane antigen (PSMA) and attractiveendogenous antibodies to the cell to which the compounds are bound,resulting in the selective and targeted cell death of those cells, inwhatever tissues they may reside, which have PSMA. The selection of alinker component is based on its documented properties ofbiocompatibility, solubility in aqueous and organic media, and lowimmunogenicity/antigenicity. Although numerous linkers may be used asotherwise described herein, a linker based upon polyethyleneglycol (PEG)linkages, polypropylene glycol linkages, orpolyethyleneglycol-co-polypropylene oligomers (up to about 100 units,about 1 to 100, about 1 to 75, about 1 to 60, about 1 to 50, about 1 to35, about 1 to 25, about 1 to 20, about 1 to 15, 1 to 10, about 8 to 12,about 1 to 8, etc.) may be favored as a linker because of the chemicaland biological characteristics of these molecules. The use ofpolyethylene (PEG) linkages is preferred.

Preferred linkers include those according to the chemical structures:

Or a polypropylene glycol or polypropylene-co-polyethylene glycol linkerhaving between 1 and 100 glycol units;Where R_(a) is H, C₁-C₃ alkyl or alkanol or forms a cyclic ring with R³(proline) and R³ is a side chain derived of an amino acid preferablyselected from the group consisting of alanine (methyl), arginine(propyleneguanidine), asparagine (methylenecarboxyamide), aspartic acid(ethanoic acid), cysteine (thiol, reduced or oxidized di-thiol),glutamine (ethylcarboxyamide), glutamic acid (propanoic acid), glycine(H), histidine (methyleneimidazole), isoleucine (1-methylpropane),leucine (2-methylpropane), lysine (butyleneamine), methionine(ethylmethylthioether), phenylalanine (benzyl), proline (R³ forms acyclic ring with R_(a) and the adjacent nitrogen group to form apyrrolidine group), serine (methanol), threonine (ethanol,1-hydroxyethane), tryptophan (methyleneindole), tyrosine (methylenephenol) or valine (isopropyl);m is an integer from 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2,3, 4 or 5; orA linker according to the chemical formula:

Where Z and Z′ are each independently a bond, —(CH₂)_(i)—O,—(CH₂)_(i)—S, —(CH₂)_(i)—N—R,

wherein said —(CH₂)_(i) group, if present in Z or Z′, is bonded to aconnector, ABT or CBT;Each R is H, or a C₁-C₃ alkyl or alkanol group;Each R² is independently H or a C₁-C₃ alkyl group;Each Y is independently a bond, O, S or N—R;Each i is independently 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1,2, 3, 4 or 5;D is

ora bond, with the proviso that Z, Z′ and D are not each simultaneouslybonds;j is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;m′ is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;n is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;X¹ is O, S or N—R; andR is as described above, or a pharmaceutical salt thereof.

The term “connector”, symbolized by [CON], is used to describe achemical moiety which is optionally included in chimeric compoundsaccording to the present invention which forms from the reaction productof an activated ABT-linker with a CBT moiety (which also is preferablyactivated) or an ABT moiety with an activated linker-CBT as otherwisedescribed herein. The connector group is the resulting moiety whichforms from the facile condensation of two separate chemical fragmentswhich contain reactive groups which can provide connector groups asotherwise described to produce chimeric compounds according to thepresent invention. It is noted that a connector may be distinguishablefrom a linker in that the connector is the result of a specificchemistry which is used provide chimeric compounds according to thepresent invention wherein the reaction product of these groups resultsin an identifiable connector group which is distinguishable from thelinker group as otherwise described herein. It is noted that there maybe some overlap between the description of the connector group and thelinker group, especially with respect to more common connector groupssuch as amide groups, oxygen (ether), sulfur (thioether) or aminelinkages, urea or carbonate —OC(O)O—groups as otherwise describedherein. It is further noted that a connector (or linker) may beconnected to ABT, a linker or CBT at positions which are represented asbeing linked to another group using the using the symbol

Where two or more such groups are present in a linker or connector, anyof an ABT, a linker or a CBT may be bonded to such a group.

Common connector groups which are used in the present invention includethe following chemical groups:

Where X² is O, S, NR⁴, S(O), S(O)₂, —S(O)₂O, —OS(O)₂, or OS(O)₂O;X³ is O, S, NR⁴; andR⁴ is H, a C₁-C₃ alkyl or alkanol group, or a —C(O)(C₁-C₃) group.

The term “pharmaceutically acceptable salt” or “salt” is used throughoutthe specification to describe a salt form of one or more of thecompositions herein which are presented to increase the solubility ofthe compound in saline for parenteral delivery or in the gastric juicesof the patient's gastrointestinal tract in order to promote dissolutionand the bioavailability of the compounds. Pharmaceutically acceptablesalts include those derived from pharmaceutically acceptable inorganicor organic bases and acids. Suitable salts include those derived fromalkali metals such as potassium and sodium, alkaline earth metals suchas calcium, magnesium and ammonium salts, among numerous other acidswell known in the pharmaceutical art. Sodium and potassium salts may bypreferred as neutralization salts of carboxylic acids and free acidphosphate containing compositions according to the present invention.The term “salt” shall mean any salt consistent with the use of thecompounds according to the present invention. In the case where thecompounds are used in pharmaceutical indications, including thetreatment of prostate cancer, including metastatic prostate cancer, theterm “salt” shall mean a pharmaceutically acceptable salt, consistentwith the use of the compounds as pharmaceutical agents.

The term “coadministration” shall mean that at least two compounds orcompositions are administered to the patient at the same time, such thateffective amounts or concentrations of each of the two or more compoundsmay be found in the patient at a given point in time. Although compoundsaccording to the present invention may be co-administered to a patientat the same time, the term embraces both administration of two or moreagents at the same time or at different times, provided that effectiveconcentrations of all coadministered compounds or compositions are foundin the subject at a given time. Chimeric antibody-recruiting compoundsaccording to the present invention may be administered with one or moreadditional anti-cancer agents or other agents which are used to treat orameliorate the symptoms of cancer, especially prostate cancer, includingmetastatic prostate cancer. Exemplary anticancer agents which may becoadministered in combination with one or more chimeric compoundsaccording to the present invention include, for example,antimetabolites, inhibitors of topoisomerase I and II, alkylating agentsand microtubule inhibitors (e.g., taxol). Specific anticancer compoundsfor use in the present invention include, for example, Aldesleukin;Alemtuzumab; alitretinoin; allopurinol; altretamine; amifostine;anastrozole; arsenic trioxide; Asparaginase; BCG Live; bexarotenecapsules; bexarotene gel; bleomycin; busulfan intravenous; busulfanoral; calusterone; capecitabine; carboplatin; carmustine; carmustinewith Polifeprosan 20 Implant; celecoxib; chlorambucil; cisplatin;cladribine; cyclophosphamide; cytarabine; cytarabine liposomal;dacarbazine; dactinomycin; actinomycin D; Darbepoetin alfa; daunorubicinliposomal; daunorubicin, daunomycin; Denileukin diftitox, dexrazoxane;docetaxel; doxorubicin; doxorubicin liposomal; Dromostanolonepropionate; Elliott's B Solution; epirubicin; Epoetin alfa estramustine;etoposide phosphate; etoposide (VP-16); exemestane; Filgrastim;floxuridine (intraarterial); fludarabine; fluorouracil (5-FU);fulvestrant; gemtuzumab ozogamicin; goserelin acetate; hydroxyurea;Ibritumomab Tiuxetan; idarubicin; ifosfamide; imatinib mesylate;Interferon alfa-2a; Interferon alfa-2b; irinotecan; letrozole;leucovorin; levamisole; lomustine (CCNU); meclorethamine (nitrogenmustard); megestrol acetate; melphalan (L-PAM); mercaptopurine (6-MP);mesna; methotrexate; methoxsalen; mitomycin C; mitotane; mitoxantrone;nandrolone phenpropionate; Nofetumomab; LOddC; Oprelvekin; oxaliplatin;paclitaxel; pamidronate; pegademase; Pegaspargase; Pegfilgrastim;pentostatin; pipobroman; plicamycin; mithramycin; porfimer sodium;procarbazine; quinacrine; Rasburicase; Rituximab; Sargramostim;streptozocin; talbuvidine (LDT); talc; tamoxifen; temozolomide;teniposide (VM-26); testolactone; thioguanine (6-TG); thiotepa;topotecan; toremifene; Tositumomab; Trastuzumab; tretinoin (ATRA);Uracil Mustard; valrubicin; valtorcitabine (monoval LDC); vinblastine;vinorelbine; zoledronate; and mixtures thereof, among others.

In addition to anticancer agents, a number of other agents may becoadministered with chimeric compounds according to the presentinvention in the treatment of cancer, especially prostate cancer,including metastatic prostate cancer. These include active agents,minerals, vitamins and nutritional supplements which have shown someefficacy in inhibiting prostate cancer tissue or its growth or areotherwise useful in the treatment of prostate cancer. For example, oneor more of dietary selenium, vitamin E, lycopene, soy foods, vitamin D,green tea, lycopene, omega-3 fatty acids and phytoestrogens, includingbeta-sitosterol, may be utilized in combination with the presentcompounds to treat prostate cancer.

In addition, active agents, other than traditional anticancer agentshave shown some utility in treating prostate cancer. The selectiveestrogen receptor modulator drug toremifene may be used in combinationwith the present compounds to treat cancer, especially prostate cancer,including metastatic prostate cancer. In addition, two medications whichblock the conversion of testosterone to dihydrotestosterone, finasterideand dutasteride, are also useful in the treatment of prostate cancerwhen coadministered with compounds according to the present invention.The phytochemicals indole-3-carbinol and diindolylmethane, may also becoadministered with the present compounds for their effects in treatingprostate cancer. Additional agents which may be combined with compoundsaccording to the present invention include antiandrogens, for example,flutamide, bicalutamide, nilutamide, and cyproterone acetate as well asagents which reduce the production of adrenal androgens (e.g. DHEA),such as ketoconazole and aminoglutethimide. Other active agents whichmay be combined with compounds according to the present inventioninclude, for example, GnRH modulators, including agonists andantagonists. GnRH antagonists suppress the production of LH directly,while GnRH agonists suppress LH through the process of downregulationafter an initial stimulation effect. Abarelix is an example of a GnRHantagonist, while the GnRH agonists include leuprolide, goserelin,triptorelin, and buserelin, among others. These agents may be combinedwith compounds according to the present invention in effective amounts.In addition, abiraterone acetate may also be combined with one or morecompounds according to the present invention in the treatment ofprostate cancer, especially including metastatic prostate cancer.

Other agents which may be combined with one or more compounds accordingto the present invention, include the bisphosphonates such as zoledronicacid, which have been shown to delay skeletal complications such asfractures which occur with patients having metastatic prostate cancer.Alpharadin, another agent, may be combined with compounds according tothe present invention to target bone metastasis. In addition, bone paindue to metastatic prostate cancer may be treated with opioid painrelievers such as morphine and oxycodone, among others, which may becombined with compounds according to the present invention.

The present invention preferably relates to compounds according to thegeneral chemical structure:

Wherein A is an antibody binding moiety according to the chemicalformula:

Where Y′ is H or NO₂;X is O, CH₂, NR¹, S(O), S(O)₂, —S(O)₂O, —OS(O)₂, or OS(O)₂O;R¹ is H, a C₁-C₃ alkyl group, or a —C(O)(C₁-C₃) group;X′ is CH₂, O, N—R¹, or S, preferably O;R^(1′) is H or C₁-C₃ alkyl;Z is a bond, a monosaccharide, disaccharide, oligosaccharide,glycoprotein or glycolipid;X^(b) is a bond, O, CH₂, NR¹ or S;X″ is O, CH₂, NR¹;R¹ is H, a C₁-C₃ alkyl group or a —C(O)(C₁-C₃) group;B is a cell binding moiety according to the chemical formula:

Where X₁ and X₂ are each independently CH₂, O, NH or S;X₃ is O, CH₂, NR¹, S(O), S(O)₂, —S(O)₂O, —OS(O)₂, or OS(O)₂O;R¹ is H, a C₁-C₃ alkyl group, or a —C(O)(C₁-C₃) group;k is an integer from 0 to 20, 8 to 12, 1 to 15, 1 to 10, 1 to 8, 1 to 6,1, 2, 3, 4, 5 or 6;L is a linker according to the chemical formula:

Or a polypropylene glycol or polypropylene-co-polyethylene glycol linkerhaving between 1 and 100 glycol units (1 to 75, 1 to 60, 1 to 55, 1 to50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to6, 1, 2, 3, 4 or 52 and 50, 3 and 45);Where R_(a) is H, C₁-C₃ alkyl or alkanol or forms a cyclic ring with R³(proline) and R³ is a side chain derived of an amino acid preferablyselected from the group consisting of alanine (methyl), arginine(propyleneguanidine), asparagine (methylenecarboxyamide), aspartic acid(ethanoic acid), cysteine (thiol, reduced or oxidized di-thiol),glutamine (ethylcarboxyamide), glutamic acid (propanoic acid), glycine(H), histidine (methyleneimidazole), isoleucine (1-methylpropane),leucine (2-methylpropane), lysine (butyleneamine), methionine(ethylmethylthioether), phenylalanine (benzyl), proline (R³ forms acyclic ring with R_(a) and the adjacent nitrogen group to form apyrrolidine group), serine (methanol), threonine (ethanol,1-hydroxyethane), tryptophan (methyleneindole), tyrosine (methylenephenol) or valine (isopropyl);m is an integer from 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2,3, 4 or 5; orL is a linker according to the chemical formula:

Where Z and Z′ are each independently a bond, —(CH₂)_(i)—O,—(CH₂)_(i)—S, —(CH₂)_(i)—N—R,

wherein said —(CH₂)_(i) group, if present in Z or Z′, is bonded to [CON]if present, ABT or CBT;Each R is independently H, or a C₁-C₃ alkyl or alkanol group;Each R² is independently H or a C₁-C₃ alkyl group;Each Y is independently a bond, O, S or N—R;Each i is independently 0 to 100, 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1to 6, 1, 2, 3, 4 or 5;D is

or a bond,with the proviso that Z, Z′ and D are not each simultaneously bonds;j is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;m′ is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;n′ is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5; andX¹ is O, S or N—R,R is as described above; andThe connector moiety [CON] is a bond or a moiety according to thechemical structure:

Where X² is O, S, NR⁴, S(O), S(O)₂, —S(O)₂O, —OS(O)₂, or OS(O)₂O;X³ is NR⁴, O or S; andR⁴ is H, a C₁-C₃ alkyl or alkanol group, or a —C(O)(C₁-C₃) group; ora pharmaceutically acceptable salt, solvate or polymorph thereof.

In preferred aspects of the invention, the antibody binding terminus(ABT) is

Y′ is NO₂;X′ is O;Z is a bond, a monosaccharide or a disaccharide.

In preferred aspects of the invention, CBT is

Where k is an integer from 0 to 20, 1 to 20, more preferably 8 to 12.

In other preferred aspects the connector moiety [CON} is a

group which can be covalently bonded at

with a ABT group, a CBT group or alternatively, a linker group toprovide compounds as otherwise described herein.

In still other preferred aspects the linker group is a oligo orpolyethyleneglycol moiety of the structure:

Where m is from 1 to 100 or as otherwise described herein, preferablyabout 8 to 12. Noted there is that polypropylene glycol or polyethyleneglycol-co-polypropylenen glycol linkers may be substituted for PEGgroups in the present compounds.

A number of preferred compounds, 20, 21, 22, 23, 24 and 25 are set forthin attached FIG. 7.

In certain preferred aspects, the compound is according to the chemicalstructure:

Where n is 0 to 12, 0 to 12, 0 to 8, 0 to 6, 1 to 4; andX is

Where Y^(N), Y^(N1) and Y′ is H or NO₂; with at least one of Y^(N),Y^(N1) and Y′ being NO₂,Or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvateor polymorph thereof.

In the above compounds, X is preferably

where Y′ is H or NO₂, preferably H,

Pharmaceutical compositions comprising combinations of an effectiveamount of at least one chimeric antibody-recruiting compound accordingto the present invention, and one or more of the compounds otherwisedescribed herein, all in effective amounts, in combination with apharmaceutically effective amount of a carrier, additive or excipient,represents a further aspect of the present invention.

The compositions of the present invention may be formulated in aconventional manner using one or more pharmaceutically acceptablecarriers and may also be administered in controlled-releaseformulations. Pharmaceutically acceptable carriers that may be used inthese pharmaceutical compositions include, but are not limited to, ionexchangers, alumina, aluminum stearate, lecithin, serum proteins, suchas human serum albumin, buffer substances such as phosphates, glycine,sorbic acid, potassium sorbate, partial glyceride mixtures of saturatedvegetable fatty acids, water, salts or electrolytes, such as prolaminesulfate, disodium hydrogen phosphate, potassium hydrogen phosphate,sodium chloride, zinc salts, colloidal silica, magnesium trisilicate,polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol,sodium carboxymethylcellulose, polyacrylates, waxes,polyethylene-polyoxypropylene-block polymers, polyethylene glycol andwool fat.

The compositions of the present invention may be administered orally,parenterally, by inhalation spray, topically, rectally, nasally,buccally, vaginally or via an implanted reservoir. The term “parenteral”as used herein includes subcutaneous, intravenous, intramuscular,intra-articular, intra-synovial, intrasternal, intrathecal,intrahepatic, intralesional and intracranial injection or infusiontechniques. Preferably, the compositions are administered orally,intraperitoneally or intravenously.

Sterile injectable forms of the compositions of this invention may beaqueous or oleaginous suspension. These suspensions may be formulatedaccording to techniques known in the art using suitable dispersing orwetting agents and suspending agents. The sterile injectable preparationmay also be a sterile injectable solution or suspension in a non-toxicparenterally-acceptable diluent or solvent, for example as a solution in1,3-butanediol. Among the acceptable vehicles and solvents that may beemployed are water, Ringer's solution and isotonic sodium chloridesolution. In addition, sterile, fixed oils are conventionally employedas a solvent or suspending medium. For this purpose, any bland fixed oilmay be employed including synthetic mono- or di-glycerides. Fatty acids,such as oleic acid and its glyceride derivatives are useful in thepreparation of injectables, as are natural pharmaceutically-acceptableoils, such as olive oil or castor oil, especially in theirpolyoxyethylated versions. These oil solutions or suspensions may alsocontain a long-chain alcohol diluent or dispersant, such as Ph. Helv orsimilar alcohol.

The pharmaceutical compositions of this invention may be orallyadministered in any orally acceptable dosage form including, but notlimited to, capsules, tablets, aqueous suspensions or solutions. In thecase of tablets for oral use, carriers which are commonly used includelactose and corn starch. Lubricating agents, such as magnesium stearate,are also typically added. For oral administration in a capsule form,useful diluents include lactose and dried corn starch. When aqueoussuspensions are required for oral use, the active ingredient is combinedwith emulsifying and suspending agents. If desired, certain sweetening,flavoring or coloring agents may also be added.

Alternatively, the pharmaceutical compositions of this invention may beadministered in the form of suppositories for rectal administration.These can be prepared by mixing the agent with a suitable non-irritatingexcipient which is solid at room temperature but liquid at rectaltemperature and therefore will melt in the rectum to release the drug.Such materials include cocoa butter, beeswax and polyethylene glycols.

The pharmaceutical compositions of this invention may also beadministered topically, especially to treat skin cancers, psoriasis orother diseases which occur in or on the skin. Suitable topicalformulations are readily prepared for each of these areas or organs.Topical application for the lower intestinal tract can be effected in arectal suppository formulation (see above) or in a suitable enemaformulation. Topically-acceptable transdermal patches may also be used.

For topical applications, the pharmaceutical compositions may beformulated in a suitable ointment containing the active componentsuspended or dissolved in one or more carriers. Carriers for topicaladministration of the compounds of this invention include, but are notlimited to, mineral oil, liquid petrolatum, white petrolatum, propyleneglycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax andwater.

Alternatively, the pharmaceutical compositions can be formulated in asuitable lotion or cream containing the active components suspended ordissolved in one or more pharmaceutically acceptable carriers. Suitablecarriers include, but are not limited to, mineral oil, sorbitanmonostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol,2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutical compositions may be formulated asmicronized suspensions in isotonic, pH adjusted sterile saline, or,preferably, as solutions in isotonic, pH adjusted sterile saline, eitherwith our without a preservative such as benzylalkonium chloride.Alternatively, for ophthalmic uses, the pharmaceutical compositions maybe formulated in an ointment such as petrolatum.

The pharmaceutical compositions of this invention may also beadministered by nasal aerosol or inhalation. Such compositions areprepared according to techniques well-known in the art of pharmaceuticalformulation and may be prepared as solutions in saline, employing benzylalcohol or other suitable preservatives, absorption promoters to enhancebioavailability, fluorocarbons, and/or other conventional solubilizingor dispersing agents.

The amount of compound in a pharmaceutical composition of the instantinvention that may be combined with the carrier materials to produce asingle dosage form will vary depending upon the host and diseasetreated, the particular mode of administration. Preferably, thecompositions should be formulated to contain between about 0.05milligram to about 750 milligrams or more, more preferably about 1milligram to about 600 milligrams, and even more preferably about 10milligrams to about 500 milligrams of active ingredient, alone or incombination with at least one additional non-antibody attractingcompound which may be used to treat cancer, prostate cancer ormetastatic prostate cancer or a secondary effect or condition thereof.

It should also be understood that a specific dosage and treatmentregimen for any particular patient will depend upon a variety offactors, including the activity of the specific compound employed, theage, body weight, general health, sex, diet, time of administration,rate of excretion, drug combination, and the judgment of the treatingphysician and the severity of the particular disease or condition beingtreated.

A patient or subject (e.g. a male human) suffering from cancer can betreated by administering to the patient (subject) an effective amount ofa chimeric antibody recruiting compound according to the presentinvention including pharmaceutically acceptable salts, solvates orpolymorphs, thereof optionally in a pharmaceutically acceptable carrieror diluent, either alone, or in combination with other known anticanceror pharmaceutical agents, preferably agents which can assist in treatingprostate cancer, including metastatic prostate cancer or ameliorate thesecondary effects and conditions associated with prostate cancer. Thistreatment can also be administered in conjunction with otherconventional cancer therapies, such as radiation treatment or surgery.

These compounds can be administered by any appropriate route, forexample, orally, parenterally, intravenously, intradermally,subcutaneously, or topically, in liquid, cream, gel, or solid form, orby aerosol form.

The active compound is included in the pharmaceutically acceptablecarrier or diluent in an amount sufficient to deliver to a patient atherapeutically effective amount for the desired indication, withoutcausing serious toxic effects in the patient treated. A preferred doseof the active compound for all of the herein-mentioned conditions is inthe range from about 10 ng/kg to 300 mg/kg, preferably 0.1 to 100 mg/kgper day, more generally 0.5 to about 25 mg per kilogram body weight ofthe recipient/patient per day. A typical topical dosage will range from0.01-3% wt/wt in a suitable carrier.

The compound is conveniently administered in any suitable unit dosageform, including but not limited to one containing less than 1 mg, 1 mgto 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosageform. An oral dosage of about 25-250 mg is often convenient.

The active ingredient is preferably administered to achieve peak plasmaconcentrations of the active compound of about 0.00001-30 mM, preferablyabout 0.1-30 μM. This may be achieved, for example, by the intravenousinjection of a solution or formulation of the active ingredient,optionally in saline, or an aqueous medium or administered as a bolus ofthe active ingredient. Oral administration is also appropriate togenerate effective plasma concentrations of active agent.

The concentration of active compound in the drug composition will dependon absorption, distribution, inactivation, and excretion rates of thedrug as well as other factors known to those of skill in the art. It isto be noted that dosage values will also vary with the severity of thecondition to be alleviated. It is to be further understood that for anyparticular subject, specific dosage regimens should be adjusted overtime according to the individual need and the professional judgment ofthe person administering or supervising the administration of thecompositions, and that the concentration ranges set forth herein areexemplary only and are not intended to limit the scope or practice ofthe claimed composition. The active ingredient may be administered atonce, or may be divided into a number of smaller doses to beadministered at varying intervals of time.

Oral compositions will generally include an inert diluent or an ediblecarrier. They may be enclosed in gelatin capsules or compressed intotablets. For the purpose of oral therapeutic administration, the activecompound or its prodrug derivative can be incorporated with excipientsand used in the form of tablets, troches, or capsules. Pharmaceuticallycompatible binding agents, and/or adjuvant materials can be included aspart of the composition.

The tablets, pills, capsules, troches and the like can contain any ofthe following ingredients, or compounds of a similar nature: a bindersuch as microcrystalline cellulose, gum tragacanth or gelatin; anexcipient such as starch or lactose, a dispersing agent such as alginicacid, Primogel, or corn starch; a lubricant such as magnesium stearateor Sterotes; a glidant such as colloidal silicon dioxide; a sweeteningagent such as sucrose or saccharin; or a flavoring agent such aspeppermint, methyl salicylate, or orange flavoring. When the dosage unitform is a capsule, it can contain, in addition to material of the abovetype, a liquid carrier such as a fatty oil. In addition, dosage unitforms can contain various other materials which modify the physical formof the dosage unit, for example, coatings of sugar, shellac, or entericagents.

The active compound or pharmaceutically acceptable salt thereof can beadministered as a component of an elixir, suspension, syrup, wafer,chewing gum or the like. A syrup may contain, in addition to the activecompounds, sucrose as a sweetening agent and certain preservatives, dyesand colorings and flavors.

The active compound or pharmaceutically acceptable salts thereof canalso be mixed with other active materials that do not impair the desiredaction, or with materials that supplement the desired action, such asother anticancer agents, antibiotics, antifungals, antiinflammatories,or antiviral compounds. In certain preferred aspects of the invention,one or more chimeric antibody-recruiting compound according to thepresent invention is coadministered with another anticancer agent and/oranother bioactive agent, as otherwise described herein.

Solutions or suspensions used for parenteral, intradermal, subcutaneous,or topical application can include the following components: a sterilediluent such as water for injection, saline solution, fixed oils,polyethylene glycols, glycerine, propylene glycol or other syntheticsolvents; antibacterial agents such as benzyl alcohol or methylparabens; antioxidants such as ascorbic acid or sodium bisulfite;chelating agents such as ethylenediaminetetraacetic acid; buffers suchas acetates, citrates or phosphates and agents for the adjustment oftonicity such as sodium chloride or dextrose. The parental preparationcan be enclosed in ampoules, disposable syringes or multiple dose vialsmade of glass or plastic.

If administered intravenously, preferred carriers are physiologicalsaline or phosphate buffered saline (PBS).

In one embodiment, the active compounds are prepared with carriers thatwill protect the compound against rapid elimination from the body, suchas a controlled release formulation, including implants andmicroencapsulated delivery systems. Biodegradable, biocompatiblepolymers can be used, such as ethylene vinyl acetate, polyanhydrides,polyglycolic acid, collagen, polyorthoesters, and polylactic acid.Methods for preparation of such formulations will be apparent to thoseskilled in the art.

Liposomal suspensions may also be pharmaceutically acceptable carriers.These may be prepared according to methods known to those skilled in theart, for example, as described in U.S. Pat. No. 4,522,811 (which isincorporated herein by reference in its entirety). For example, liposomeformulations may be prepared by dissolving appropriate lipid(s) (such asstearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline,arachadoyl phosphatidyl choline, and cholesterol) in an inorganicsolvent that is then evaporated, leaving behind a thin film of driedlipid on the surface of the container. An aqueous solution of the activecompound are then introduced into the container. The container is thenswirled by hand to free lipid material from the sides of the containerand to disperse lipid aggregates, thereby forming the liposomalsuspension.

General Chemical Synthesis

The chimeric antibody-recruiting compounds according to the presentinvention may be synthesized readily using standard chemicalconnectivity between the linker and cell binding terminus (CBT) and theantibody binding terminus (ABT), along with appropriate protectinggroups when necessary. The approach uses standard functional groupchemistry in order to link a cell binding moiety to an antibody bindingmoiety through a linker, which, in preferred aspects, provides anoptional connector moiety (between the linker and the ABT or the linkerand the CBT depending on functional groups, reactions used, etc.) whichforms when the CBT is covalently bonded (connected) to the ABT antibodybinding through the linker. Noted here is the fact that the connectormoiety per se is not required and the linker, as otherwise describedherein, may be covalently bonded directly to a CBT and/or an ABT withoutthe formation of a specific connector moiety. In the present invention,the connector moiety, which is preferably included in chimericantibody-recruiting compounds according to the present invention,reflects its formation reflective of favorable synthetic chemistries toprovide chimeric compounds as otherwise disclosed herein.

As depicted in the general scheme below, a carboxylic acid, such L-A,could be coupled to either an amine or an alcohol, such as C-A, togenerate esters or amides through standard carbodiimide conditions (DCC,EDC, DIC along with base and catalytic amine (DMAP, imidazole), byconversion to the acid chloride through oxaly chloride or thionylchloride etc. followed by addition of amine/alcohol.

Additionally, for example, an amine or an alcohol, such as A-A, can becoupled to an isocyanate or an isothiocyanate, such as C-E, to generateureas, thioureas, or the corresponding carbonates or thiocarbonates.

In yet another approach, a triazole may be synthesized through acycloaddition reaction between an azide, such as C-B, and an alkyne,such as L-C. This can be catalyzed by copper, such as copper sulfatealong with ascorbic acid, to facilitate a clean reaction.

Still, in a further approach, for example, a heterolinker can be madethrough treating a nucleophile, such as A-A, with the appropriateleaving group, such as L-E. Some leaving groups could be halogens, suchas bromine, or sulfonates, such as triflates or tosylates.

A-A

L-A

C-A

A-B

L-B

C-B

A-C

L-C

C-C

A-D

L-D

C-D

A-E

L-E

C-E

A-F

C-F LG = leaving group, such as Cl, Br, OTs, ect. PG = protecting group,such as t-Bu, Bn, etc.Compounds

Several high affinity ligands have been developed to target PSMAselectively. See, Slusher, et al, Nature Medicine, 1999, 5, 1396. FIG. 1depicts the small molecule templated immunotherapy which is generallyunderstood to represent the principal mechanism of chimericantibody-recruiting compounds according to the present invention. PC-ARM(3, FIG. 3) was inspired by a urea-based, tetrazole-containing ligandwith exceptionally high affinity (2, Ki=0.9 nM) {See, Kozikowski, J.Med. Chem., 2004, 47, 1729] and refined with molecular modeling toaccommodate a solvent-exposed appendage (FIG. 2A). A model of thisoverall ternary complex (FIG. 2B) suggested that a sizeable tetherlength would be required (8-12 polyethylene glycol units).

The azide-functionalized cell-binding terminus was synthesized in 3steps by coupling Cbz-protected lysine and t-butyl protected glutamicacid with triphosgene (See, Kozikowski, et al., J. Med. Chem., 2004, 47,1729) followed by Cbz deprotection and azide formation (Scheme 2, FIG.4). Link, et al., J. Am. Chem. Soc., 2004, 126, 10598.Heterobifunctional PEG 10 was synthesized in a five step process fromoctaethylene glycol (Scheme 2, FIG. 4). Natarajan, et al., J. Chem.Comm., 2007, 7, 695. These intermediates were coupled via microwaveassisted, copper-catalyzed Huisgen cyloaddition, (Bouillon, et al., J.Org. Chem., 2006, 71, 4700) and deprotected using microwave assisted TFAdeprotection (Scheme 3, FIG. 4) afforded PC-ARM (3). This specificsynthesis may be genericized and applied to produce a large number ofcompounds according to the present invention simply following theexperimental section set forth hereinbelow. Inhibition experimentsagainst a human recombinant PSMA (R&D Research) confirmed indirectlythat this long-tethered molecule could bind PSMA with high affinity(Ki=0.9±0.3 nM).

In order to confirm the antibody-recruiting capability of oursmall-molecule, live-cell recruitment assays were performed withPSMA-expressing LNCaP cells and Alexafluor488 conjugated anti-DNPantibodies. In the presence of anti-DNP antibodies, only a small shiftwas observed, likely due to non-specific binding. However, when chimericmolecule 3 was added, an increase in fluorescence was observed,indicating the formation of the desired ternary complex formation (FIG.5A). In fact, this increase in fluorescence could be observed atconcentrations well into the picomolar concentration range, suggestingexceptional activity. An observed decrease in fluorescence with theaddition of either 2-phosphonomethyl pentanedioic acid (Slusher, et al.,Nature Medicine, 1999, 5, 1396) or di-DNP lysine confirmed that therecruitment was the result of both the cell-binding and antibody-bindingtermini. In addition, cells expressing no PSMA showed no significantincrease in fluorescence (FIG. 5B).

Further, the ability of our molecules to induce cell killing was tested.While small-molecule (3) induced increases in cell-killing were notseen, or were modest, (<20%) using a complement-dependant cytotoxicityassays in the presence of anti-DNP antibodies, significant increases incell-death was observed in preliminary antibody-dependant cell-mediatedcytotoxicity assay (ADCC). In the presence of anti-DNP antibodies andhuman peripheral blood mononuclear cells, 3 is shown to mediate cellkilling of up to 40% on LNCaP cells. Furthermore, 3 alone does not showcytotoxicity, and ADCC does not occur on PSMA-DU145 cells (FIG. 6).These results are consistent with reports of naked monoclonal antibodiesto PSMA being capable inducing ADCC but not CDC responses. Deo, et al.,international patent publication WO2003/064606. Current work is underwayto confirm these results, and better understand the mode of action, suchas the specific effector cells that mediate the killing.

Alternative Compounds

Alternatively, in relying on the above described general approach,molecule (4) (FIG. 9) may be readily synthesized and used as a synthonfor the chemical synthesis of dimeric compounds according to the presentinvention. Compound 4 or similar synthetically manageable molecules thathave a propargyl tether that can be used for click chemistry (Scheme 1a,FIG. 9). See, Sharpless and Manetsch, Expert Opinion on Drug Discovery2006, 1, 525-538. Treating this molecule to azides 5 and 6 withvariously lengthened polyethylene glycol units allows rapid entry into agroup of chimeric recruiting molecules of different tether lengths.Having the flexibility to alter the chain length is important to assistin identifying an optimal CBT-ABT distance.

Efforts toward alkyne 4 have provided us with bromide intermediate 12,which will generate our target through an Arbuzov reaction with knownphosphate 13 (Scheme 2a, FIG. 10). See, Jackson, et al., J. Med. Chem.2001, 44, 4170-4175. Sonogashira coupling of 7 and 8 provides the carbonframework for the linker, (Liu and Stahl, J. Am. Chem. Soc.; 2007; 129;6328-6335) and LAH reducing conditions generates 10 in the appropriatetrans-substituted orientation (Luo, et al., Chem. Comm. 2007, 2136-2138)and deprotects the acyl group. This newly deprotected phenol isselectively deprotonated over the homoallylic alcohol with potassiumcarbonate and trapped with propargyl bromide to generate 11. Theremaining alcohol can then be converted to an alkyl bromide through theuse of phosphorous tribromide.

The synthesis of the azide coupling partners is also provided. SeeScheme 3, FIG. 11. The focus was on azide 15 because bis-DNP lysineattached to polyethylene glycol linkers has demonstrated significantaffinity toward anti-DNP antibodies. See, Baird, et al. Biochem. 2003,42, 12739-12748. This particular azide, which possesses 3 polyethyleneglycol units, was synthesized in one-pot from commercially availablebis(2,4-dinitrophenyl)-lysine and 11-azido-3,6,9-trioxaundecan-1-amine.This was accomplished through a Schotten-Bauman protocol to provide thedesired product in an unoptimized yield of 40%. Demko, et al., J. Org.Chem. 2001, 66, 7945-7950. Scheme 3a, FIG. 11. Alternatively, mono DNPazide 16 may be readily prepared through nucleophilic aromaticsubstitution.

Synthesis of Polyvalent Derivatives

Polyvalent derivatives can be synthesized in a divergent manner from thepreviously proposed intermediates. Synthetically complementarybis-alkynyl and tris-azidyl compounds are known, and can be used veryeffectively in this pursuit. Bis-alkynyl 20 can be converted under clickconditions with a longer PEG-derived azido-DNP 19, to generate thedesired bis-di DNP analog 21 (Scheme 4a, FIG. 12).

The tris-azidylated analog can be synthesized in a similar manner from aknown triazide 23. See Scheme 5a, FIG. 13. See, Kale, et al., Biorg.Med. Chem. Lett. 2007, 17, 2459-2464. This triazide can undergo clickchemistry with protected intermediate 22 to provide trimeric 2-PMPAanalog 24. With these synthetic pieces (synthons) in hand, the finalmolecule can be put together by standard peptide coupling followed byTFA deprotection. The final compound is presented in FIG. 8 (compound3).

The experiments conducted and presented here demonstrate thatsmall-molecule antibody-recruiting molecules which bind selectively toprostate-specific membrane antigen can recruit antibodies toPSMA-expressing cells and induce cell killing. This small-moleculemediated response represents a new treatment for cancer.

The present invention is further described by way of the presentation ofthe following examples. While these examples are to be taken asexemplary of the present invention, they are not limiting in any way.

Examples General Information

Unless otherwise stated, all reactions are carried out in flame-driedglassware under a nitrogen atmosphere. All reagents were purchased fromcommercial suppliers and used without further purification except thefollowing: Triethylamine was distilled over calcium hydride; CH₂Cl₂,PhMe, DMF, and THF were purified using a solvent dispensing system;Water was purified using a Milli-Q purification system.

Infrared (IR) spectra bands are characterized as broad (br), strong (s),medium (m) and weak (w). ¹H NMR chemical shifts are reported with thesolvent residual peak as the internal standard (CDCl₃ δ 7.26 ppm orCD₃OD δ 3.31 ppm). Data are reported as follows: chemical shift,integration, multiplicity (s=singlet, d=doublet, t=triplet, q=quartet,br=broad, m=multiplet), and coupling constants (Hz). ¹³C NMR chemicalshifts are reported in ppm with the solvent as an internal reference(CDCl₃ δ 77.2 ppm

Synthesis

1-azido-3,6,9,12,15,18,21,24-octaoxaheptacos-26-yne (azido-PEG8-yne):23-Azido-3,6,9,12,15,18,21-heptaoxatricosan-1-ol (azido-PEG8-ol)

(1.1 g, 3.17 mmol, 1.0 equiv.) was dissolved in N,N′-dimethylformamide(6 mL), and sodium hydride (152 mg, 6.34 mmol, 2.0 equiv.) was added,followed by propargyl bromide (80% in PhMe, 683 μL, 6.34 mmol, 2.0equiv.). The reaction ran for 4 h at rt, at which time it was foundcomplete by NMR aliquot. The reaction was taken up in CH₂Cl₂ (25 mL) andwashed with a saturated aqueous ammonium chloride solution (25 mL). Theaqueous solution was back-extracted with dichloromethane (2×10 mL), andcombined organics were dried over MgSO₄ and concentrated to a brown oil.Chromatography (3 cm×20 cm Silica gel, 3% MeOH/CH₂Cl₂) yieldedazido-PEG8-yne (960 mg, 78% yield). IR (thin film/NaCl) 2874 (m), 2110(m), 1160 (s), 1105 (s) cm⁻¹; ¹HNMR (400 MHz, CDCl₃) δ 4.20 (d, J=2.4Hz, 2H), 3.58 (m, 30H), 3.39 (t, J=5.1 Hz, 2H), 2.43 (t, J=2.4 Hz, 1H),1.82 (s, 1H); ¹³CNMR (125 MHz, CDCl₃) δ 79.82, 74.72, 70.75, 7022,68.27, 58.62, 50.84; HRMS (ES+) calc'd for C₁₉H₃₅N₃O₈ (M+Na) m/z456.231637. Found 456.23182.

3,6,9,12,15,18,21,24-oetaoxaheptacos-26-yn-1-amine (9):23-Azido-3,6,9,12,15,18,21-heptaoxatricosan-1-ol (azido-PEG8-yne)

(960 mg, 2.52 mmol, 1 equiv.), triphenylphosphine (992 mg, 3.78 mmol,1.5 equiv.), and water (68 μL, 3.78 mmol, 1.5 equiv.) were dissolved inTHF (10 mL) and stirred for 12 h. Reaction was concentrated andchromatographed (3 cm×20 cm Silica, CH₂Cl₂ then ramp to 80:20:1CH₂Cl₂:MeOH:Et₃N) and concentrated to yield3,6,9,12,15,18,21,24-oetaoxaheptacos-26-yn-1-amine (9) as a clear oil(815 mg, 91% yield). IR (thin film, NaCl) 3105 (br), 2914 (m), 1781 (m),1638 (m), 1169 (s) cm⁻¹. ¹H-NMR (500 MHz, CDCl₃) δ 4.17 (d, 2H, J=2.4),3.66-3.57 (m, 28H), 3.54 (t, 2H, J=5.3 Hz), 2.88 (t, 2H, J=5.0 Hz), 2.41(t, 1H, J=2.4 Hz), 2.18 (br s, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 79.52,74.59, 72.54, 70.41, 70.38, 70.38, 70.35, 70.31, 70.20, 70.06, 68.90,58.20, 41.44. HRMS (ES+) calc'd for C₁₉H₃₇NO₈ (M+H) m/z 408.259194.Found 408.25712.

N-(2,4-dinitrophenyl)-3,6,9,12,15,18,21,24-oetaoxaheptacos-26-yn-1-amine(10)

3,6,9,12-tetraoxapentadec-14-yn-1-amine (815 mg, 2.27 mmol, 1 equiv.)was dissolved in EtOH (10 mL), and triethylamine (666 μL, 0.726 mmol,1.5 equiv.) and 1-chloro-2,4-dinitrobenzene (505 mg, 2.5 mmol, 1.5equiv.) were added. The reaction flask was fitted with a refluxcondenser and the reaction was heated to reflux for 48 h, cooled, andconcentrated to a yellow oil. The crude mixture was purified by flashchromatography (3 cm×20 cm Silica, 3% MeOH:CH₂Cl₂) to yieldN-(2,4-dinitrophenyl)-3,6,9,12,15,18,21,24-octaoxaheptacos-26-yn-1-amine(10) as a yellow solid (1.15 g, >95% yield). IR (thin film/NaCl) 3363(w), 2871 (s), 1621 (s), 1337 (m), 1103 (s) cm⁻¹; ¹H-NMR (500 MHz,CDCl₃) δ 9.08 (d, 1H, J=2.6 Hz), 8.77 (bs, 1H), 8.21 (dd, 1H, J=2.6,J=9.5 Hz), 6.94 (d, 1H, J=9.5 Hz), 4.16 (6, 2H, J=2.4 Hz), 3.78 (t, 2H,J=5.0 Hz), 3.64 (m, 32H), 3.58 (q, 2H), 2.41 (t, 1H, 2.38 Hz); ¹³C-NMR(125 MHz, CDCl₃) δ 148.5, 136.1, 130.5, 130.29, 124.3, 114.3, 79.8,74.6, 70.7, 70.6, 70.5, 69.2, 68.7, 58.5, 43.3; HRMS (EI) calc'd forC₂₅H₃₉N₃O₁₂ (M+H) m/z 574.260650. Found 574.26106.

(9S,13S)-tri-tert-butyl3,11-dioxo-1-phenyl-2-oxa-4,10,12-triazapentadecane-9,13,15-tricarboxylate(12)

11(1.0 g, 3.38 mmol, 1.0 equiv.) and triethylamine (1.54 mL, 11.09 mmol,3.28 equiv.) were dissolved in dichloromethane (30 mL) and cooled to−78° C. Triphosgene (341 mg, 1.15 mmol, 0.34 equiv.) in dichloromethane(10 mL) was added dropwise to the reaction mixture. Upon completeaddition, the reaction was allowed to warm to room temperature andstirred for 30 minutes. 12 (757 mg, 2.03 mmol, 0.6 equiv) was added,followed by the addition of triethylamine (283 μL, 2.03 mmol, 0.6equiv.). The reaction was allowed to stir at room temperature overnightfor 16 hours. The reaction was then diluted with dichloromethane (50mL), and washed with water (100 mL×2). The crude mixture was dried overNa₂SO₄ and concentrated under reduced pressure. Column chromatography(Silica 1.5:1 hexane:ethyl acetate) yielded 4 (1.09 g, 86%) as acolorless oil with the following spectral characteristics: IR (thinfilm/KBr) 3342, 2976, 1731, 1650, 1552, 1454, 1368, 1255, and 1153 cm⁻¹;¹H NMR (500 MHz, CDCl₃) δ 7.35 (d, J=3.75 Hz, 4H), 7.33-7.30 (m, 1H),5.10 (d, J=4.55 Hz, 2H), 5.06-5.01 (m, 2H), 4.99 (s, 1H), 4.34-4.31 (m,2H), 3.20-3.18 (m, 2H), 2.36-2.23 (m, 2H), 2.10-2.03 (m, 1H), 1.88-1.75(m, 2H), 1.65-1.57 (m, 1H), 1.57-1.45 (m, 2H), 1.453 (s, 9H), 1.446 (s,9H), 1.43 (s, 9H), 1.40-1.30 (m, 2H); ¹³C NMR (125 MHz, CDCl₃)

172.6, 172.5, 172.2, 136.8, 128.6, 128.5, 128.2, 82.2, 82.0, 80.7, 66.7,53.4, 53.2, 40.7, 32.8, 31.7, 29.4, 28.5, 28.2, 28.1, 22.3; HRMS (EI+)m/z 622.3695 [calc'd for C₃₂H₅₁N₃O₉ (M+H)+622.3698].

(S)-di-tert-butyl2-(3-((S)-6-amino-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate(12)

X (2.35 g, 3.78 mmol, 1.0 equiv.) was dissolved in methanol (37.8 ml)and was added dropwise to a vigorously stirred reaction flask containingdry 10% Pd/C (475 mg). H₂ was bubbled through the solution for 1-2 m,and then ran for 13 h under a balloon of H₂. The reaction was deemedcomplete by TLC (Rf=0.48 in 10% MeOH/CH₂Cl₂), plugged through celite,and concentrated to give a viscous oil, which was carried on withoutfurther purification.

(S)-di-tert-butyl2-(3-((S)-6-azido-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate(14)

Sodium azide (2.629 g, 40.75 mmol, 10.0 equiv.) was dissolved in water(7.63 mL), and dichloromethane (12.91 mL) was added. The reactionmixture was cooled to 0° C. and triflic anhydride (1.36 mL, 8.09 mmol,2.0 equiv.) was added. The solution was stirred for 3 h at rt, and theorganic layer was separated from the aqueous layer. The aqueous layerwas extracted with dichloromethane (3×4 mL). The organic layers werecombined and washed with aqueous Na₂CO_(3(aq)) to give 25 ml of 0.391 MTfN₃, Amine 13 (1.97 g, 4.04 mmol, 1.0 equiv.) was dissolved in water(14.37 mL) and methanol (28.74). To this solution were added CuSO₄-5H₂O(10.1 mg, 0.04 mmol, 0.01 equiv.) and K₂CO₃ (837.5 mg, 6.06 mmol, 1.5equiv.). The TfN₃ solution (25 ml, 8.09 mmol, 2 equiv.) was addedrapidly to the stirring solution of 13, and the reaction stirred for 19h at rt. The organic layer was separated from the aqueous layer, and thewater/methanol layer was extracted once with dichloromethane. Thecombined organic layers were dried over MgSO4, concentrated underreduced pressure, and purified by column chromatography to yield 14 as awhite solid (1.440 g, 71%). R_(f)=0.68 in 10% MeOH:CH₂Cl₂. IR (Thinfilm/NaCl) 3335, 2980, 2933, 2868, 2097, 1733, 1635, 1560, 1368, 1257,and 1155 cm⁻¹; ¹HNMR (500 MHz, CDCl₃) δ 5.01 (d, J=8.25 Hz, 2H), 4.34(m, 2H), 3.26 (t, J=7.4 Hz, 2H), 2.35-2.25 (m, 2H), 2.09-2.05 (m, 1H),1.87-1.76 (m, 2H), 1.66-1.55 (m, 3H), 1.46 (s, 18H), 1.43 (s, 9H),1.45-1.35 (m, 2H) ppm; ¹³CNMR (125 MHz, CDCl₃) δ 172.6, 172.4, 172.2,156.8, 82.3, 82.1, 80.7, 53.4, 53.2, 51.3, 33.0, 31.7, 28.6, 28.5, 28.2,28.1, 22.4 ppm; HRMS (EI+) m/z 514.3225 [calc'd for C₂₄H₄₃N₅O₇(M+H)+514.3235].

(S)-di-tert-butyl2-(3-((S)-1-tert-butoxy-6-(4-(13-(2,4-dinitrophenylamino)-2,5,8,11-tetraoxatridecyl)-1H-1,2,3-triazol-1-yl)-1-oxohexan-2-yl)ureido)pentanedioate(3)

To a mixture of 10 (76 mg, 0.145 mmol, 1.0 equiv) and 14 (74.4 mg, 0.145mmol, 1.0 equiv.) in water (1 mL) and tert-butanol (1 mL) in a 5 mlμwave reaction tube was added sodium ascorbate (7 mg, 0.036 mmol, 0.25equiv.) and aqueous solution of 0.1 M copper (II) sulfate (0.0725 ml,0.00725 mmol, 0.05 equiv.). The tube was capped, and subjected tomicrowave radiation for 10 minutes at 110° C. The reaction was thenconcentrated and redissolved in trifluoroacetic acid (2 mL) anddichloromethane (1 mL) in a 5 ml microwave reaction tube. The tube wascapped and subjected to microwave radiation for 2 m at 70° C. Theresulting reaction mixture was concentrated under reduced pressure,chromatographed using HPLC, and concentrated to yield 3 (87 mg, 58%yield) as a yellow oil. IR (thin film/NaCl) 3359 (w), 2925 (s), 1737(s), 1622 (m), 1170 (s) cm⁻¹; ¹HNMR (100 MHz, MeOD) δ 9.07 (d, J=2.7 Hz,1H), 8.33 (dd, J=2.7, 9.6 Hz, 1H), 8.03 (s, 1H), 7.27 (d, J=9.6 Hz, 1H),4.66 (s, 2H), 4.45 (t, J=7 Hz, 2H), 4.35-4.28 (m, 2H), 3.83 (t, J=7 Hz,2H), 3.73-3.61 (m, 32H), 2.44-2.36 (m, 2H), 2.17-2.08 (m, 1H), 1.99-1.82(m, 4H), 1.71-1.64 (m, 1H), 1.46-1.38 (m, 2H); ¹³CNMR (125 MHz, MeOD) δ176.4, 176.1, 175.7, 160.0, 149.9, 145.9, 137.0, 131.5, 131.0, 125.2,124.7, 116.1, 71.6, 71.6, 71.5, 71.5, 70.9, 69.9, 64.8, 53.7, 53.5,51.2, 44.1, 32.8, 31.1, 30.6, 28.8, 23.4 ppm; HRMS (ES+) calc'd forC₃₇H₅₈N₈O₁₉ (M+H) m/z 919.389098. Found 919.38801.NAALADase Inhibition Experiments

A 10 mM stock solution of N-acetyl-aspartyl-glutamate (NAAG) in 40 mMNaOH was diluted to 40 μM in Tris buffer (0.1M Tris-HCl, pH=7.5), andwas added to 384 well plate (25 μl per well). For Km measurements andcontrols, 2× dilution (40 μM-312 nM) series of NAAG were made and addedto separate wells. For IC₅₀ measurements, solutions of recruitingmolecule 3 in water (2 μL per well, dilution series) were added towells. For all other wells, 2 μL of water was added. To initiatereactions, rhPSMA (R&D research) diluted in Tris buffer (20 pg/mL), wasadded to each well (25 μl per well). For negative controls, Tris bufferwas added (25 μl per well). The plate was covered and incubated for 15minutes, at which time the protein was deactivated by heating the plateto 95° C. for 3 minutes. After plate was allowed to cool, glutamic acidrelease was visualized using an Amplex®-Red glutamic acid/glutamateoxidase assay kit (Invitrogen). Km and IC₅₀ values were calculated usinggraphpad prism software, and Ki was calculated from these values usingthe Cheng-Prusoff Equation. This process was run in triplicate, and isreported in the manuscript as the average of three runs±standarddeviation.

Flow Cytometry Recruiting Experiments

Antibody Recruitment Flow Cytometry:

LNCaP and DU145 cells were detached, counted, washed, and resuspendedwith flow cytometry buffer (25 mM Tris-HCl, 150 mM NaCl, 1.5% BSA, 5 mMGlucose, 1.5 mM MgCl₂, pH 7.2) to a density of 2×10⁵ cells mL⁻¹ ofbuffer, and 1 mL was added to each epindorf tube per experiment.Solutions of 3 in water (2 μL, variable concentration per experiment) inflow cytometry buffer were added to the cells, and the cells wereincubated at 4° C. for 60 minutes. For cell-binding termini competitionexperiments, solutions of PMPA in water (2 μL, variable concentrations)were added prior to incubation. Following incubation, the cells werewashed three times with flow cytometry buffer. 20 μL of 1 mg ml⁻¹ humanIgG in mouse serum were added to each tube and the tubes were incubatedfor 5 minutes at room temperature to allow blocking of Fc receptors. 200μL of flow cytometry buffer were added, and to that was added 2 μL of 2mg ml⁻¹ AlexaFluor488 conjugated rabbit anti-dinitrophenyl IgG—fractionKLH. For antibody-binding terminus competition experiments, a solutionof di-DNP Lysine (2 μL of 5 mM solution in water) was added prior toincubation. The tubes were incubated at 4° C. for 60 minutes and takenup with 850 μL of flow cytometry buffer. The cells were spun down andwashed with flow cytometry buffer (2×1 mL). The cells were taken up with1 mL of Tris buffered saline (25 mM TrisHCl, 150 mM NaCl, pH 7.2) and 2μL of 500 μg mL⁻¹ of propidium iodide was added, and samples wereanalyzed immediately on FACSCalibur instrument (Becton Dickinson). Thedata was analyzed using FlowJo (Tree Star Inc.), gating for live cellson FL-3. An experiment omitting 3 was done as a control. The experimentwas repeated in triplicate to ensure reproducibility.

Further Examples

The following experiments relate to a number of additional compounds,i.e., antibody-recruiting molecules targeting prostate cancer (ARM-Ps)which were synthesized and tested for binding affinity and/or inhibitionof PMSA. ARM-Ps belong to a class of glutamate urea compounds capable ofinhibiting PSMA with high potency. See FIG. 14.

During the course of developing ARM-Ps, the inventors observed thatbifunctional DNP-containing conjugates were strikingly more potent thanthe parent glutamate urea compounds from which they were derived.Furthermore, we also noted that potency increases were correlated to thelength of the linker regions connecting the two poles of the molecule.Here we provide a molecular basis for these findings, which involves thedisclosure of a previously unreported arene-binding site on PSMA. Theseconclusions are supported by extensive biochemical, crystallographic,and computational studies.

Synthesis:

All starting materials and reagents were purchased from commerciallyavailable sources and used without further purification. ¹H NMR shiftsare measured using the solvent residual peak as the internal standard(CDCl_(3 □)7.26, MeOD □3.31), and reported as follows: chemical shift,multiplicity (s=singlet, bs=broad singlet, d=doublet, t=triplet,dd=doublet of doublet, q=quartet, m=multiplet), coupling constant (Hz),integration. ¹³C NMR shifts are measured using the solvent residual peakas the internal standard (CDCl_(3 □)77.20 or MeOD □49.00 orDMSO-d_(6 □)39.01), and reported as chemical shifts. Infrared (IR)spectral bands are characterized as broad (br), strong (s), medium (m),and weak (w).

Chemical Synthesis

2,4-dinitro-N-(2-(prop-2-ynyloxy)ethyl)aniline (s-2a)

2-(2,4-dinitrophenylamino)ethanol (s-1a) (410 mg, 1.80 mmol, 1.0 equiv.)was dissolved in 3 mL of DMF and slowly added to a slurry of NaH (86.4mg, 3.6 mmol, 2 equiv.) in 5 mL of DMF in a flame dried flask pre-cooledto 0° C. To the resulting slurry, 80% propargyl bromide (0.240 mL, 2.16mmol, 1.2 equiv.) in toluene, cooled to 0° C., was added slowly. The icebath was removed and the reaction was allowed to stir at roomtemperature for an additional 15 hours. The reaction was then re-cooledto 0° C., quenched with saturated NH₄Cl, and extracted with diethylether (3×150 mL). The organic layers were combined, dried, concentratedunder reduced pressure, and chromatographed (silica gel, 1×25 cm, 0%CH₃OH in CHCl₃, then 2.5% CH₃OH in CHCl₃) to yield2,4-dinitro-N-(2-(prop-2-ynyloxy)ethyl)aniline (s-2a) as a dark yellowsolid (310 mg, 64.8%). IR (thin film) 3356 (m), 3285 (m), 3105 (w), 2871(w), 2117 (w), 1616 (s), 1584 (s), 1521 (s), 1499 (m), 1423 (m), 1274(s), 1089 (s), 920 (m); ¹H NMR (400 MHz, CDCl₃) δ 9.16 (d, J=2.6 Hz,1H), 8.76 (bs, 1H), 8.28 (dd, J=9.5, 2.7 Hz, 1H), 6.96 (d, J=9.5 Hz,1H), 4.25 (d, J=2.4 Hz, 2H), 3.91-3.84 (m, 2H), 3.65 (d, J=5.3 Hz, 1H),2.50 (t, J=2.4 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 149.5, 136.3, 130.7,130.4, 124.4, 114.1, 78.9, 75.5, 67.3, 58.7, 43.3. HRMS (ES+) calc'd forC₁₁H₁₁N₃O₅ (M+H) m/z 266.0732 Found 266.0771.

2,4-dinitro-N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)aniline (s-2b)

2-(2-(2,4-dinitrophenylamino)ethoxy)ethanol (s-1b) (100 mg, 0.369 mmol,1.0 equiv.) was dissolved in 0.81 mL of DMF and slowly added to a slurryof NaH (17.71 mg, 0.738 mmol, 2.0 equiv.) in 0.81 mL of DMF in a flamedried flask pre-cooled to 0° C. An 80% solution of propargyl bromide intoluene (0.0490 □L, 0.443 mmol, 1.2 equiv.) was added slowly. The icebath was then removed and the reaction was allowed to stir at roomtemperature for an additional 2 hours. The reaction was then re-cooledto 0° C., quenched with saturated NH₄Cl, and then extracted with diethylether (3×50 mL). The organic layers were combined, dried with Na₂SO₄,concentrated under reduced pressure, and chromatographed (silica gel,3×25 cm, 0% EtOAc in hexanes, then 10% EtOAc in hexanes, then 20% EtOAcin hexanes, then 30% EtOAc in hexanes) to yield2,4-dinitro-N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)aniline (s-2b) as adark yellow solid (50 mg, 45% yield). IR (thin film) 3360 (m), 3285 (m),3107 (w), 2872 (m), 1621 (s), 1588 (m), 1524 (m), 1425 (w), 1335 (s),1305 (m), 1133 (m), 1101 (m), 920 (w), 832 (w); ¹H NMR (500 MHz, CDCl₃)δ 9.15 (d, J=2.6 Hz, 1H), 8.81 (bs, 1H), 8.27 (dd, J=9.4, 2.3 Hz, 1H),6.96 (d, J=9.5 Hz, 1H), 4.21 (d, J=2.3 Hz, 2H), 3.84 (t, J=5.2 Hz, 2H),3.74 (m, 4H), 3.61 (q, J=5.2 Hz, 2H), 2.44 (t, J=2.3 Hz, 1H). ¹³C NMR(125 MHz, CDCl₃) δ 148.6, 136.3, 130.7, 130.4, 124.4, 114.2, 79.6, 74.9,70.7, 69.3, 68.9, 58.7, 43.4. HRMS (ES+) calc'd for C₁₃H₁₅N₃O₆ (M+H) m/z310.0994 Found 310.1033.

3-(2-(2-azidoethoxy)ethoxy)prop-1-yne (s-4)

2-(2-azidoethoxy)ethanol¹ (s-3) (3 g, 22.89 mmol, 1.0 equiv.) was slowlyadded to a slurry of NaH (1.10 g, 45.78 mmol, 2 equiv.) in 102.64 mL ofDMF in a flame dried flask pre-cooled to 0° C. To the resulting slurry,80% propargyl bromide in toluene (3.06 mL, 27.47 mmol, 1.2 equiv.),cooled to 0° C., was added slowly. The ice bath was removed and thereaction was allowed to stir at room temperature for an additional 3hours. The reaction was then re-cooled to 0° C., and 3 mL of cold H₂Owas added to quench the reaction, after which the reaction wasconcentrated under reduced pressure and taken up with saturated NH₄Cl.The reaction was extracted with diethyl ether, dried with Na₂SO₄,concentrated under reduced pressure, and chromatographed (silica gel,3×25 cm, 0% CH₃OH in CHCl₃, then 10% MeOH in CHCl₃) to yield3-(2-(2-azidoethoxy)ethoxy)prop-1-yne (s-4) as a dark brown oil (2.79 g,72.1%). IR (thin film) 3291 (m), 2867 (m), 2099 (s), 1442 (w), 1347 (w),1285 (m), 1101 (s), 1032 (w), 920 (w), 942 (w), 646 (m); ¹H NMR (125MHz, CDCl₃) δ 4.21 (d, J=2.4 Hz, 1H), 3.74-3.65 (m, 3H), 3.40 (t, J=5.1Hz, 1H), 2.43 (t, J=2.4 Hz, 0H). ¹³C NMR (125 MHz, CDCl₃) δ 79.5, 74.6,70.5, 70.0, 69.1, 58.5, 50.6. HRMS (ES+) calc'd for C₇H₁₁N₃O₂ (M+H) m/z170.0885 Found 170.0924.

2-(2-(prop-2-ynyloxy)ethoxy)ethanamine (s-5)

3-(2-(2-azidoethoxy)ethoxy)prop-1-yne (s-4) (2 g, 11.82 mmol, 1.0 equiv)was dissolved in THF (30.5 mL). Triphenylphosphine (3.72 g, 14.20 mmol,1.2 equiv.) and water (0.21 mL, 11.83 mol, 1.0 equiv.) were added to thesolution and the reaction was allowed to stir at room temperature for 10hours. The reaction was concentrated under reduced pressure andchromatographed (5% CH₃OH in CHCl₃, then 5% CH₃OH in CHCl₃+5% Et₃N) toyield 2-(2-(prop-2-ynyloxy)ethoxy)ethanamine (s-5) as a pale green oil(1.35 g, 80%). IR (thin film) 3250 (m), 2863 (m), 2112 (w), 1589 (w),1443 (w), 1349 (m), 1291 (w), 1093 (s), 1037 (m), 918 (w), 840 (w), 673(m); ¹H NMR (500 MHz, CDCl₃) δ 4.21 (d, J=2.3 Hz, 2H), 3.73-3.68 (m,2H), 3.68-3.62 (m, 2H), 3.51 (t, J=5.2 Hz, 2H), 2.87 (t, J=5.2 Hz, 2H),2.43 (dd, J=2.4 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 79.7, 74.7, 73.7,70.3, 69.2, 58.6, 41.9. HRMS (ES+) calc'd for C₇H₁₃NO₂ (M+H) m/z144.0980 Found 144.1019.

2-nitro-N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)aniline (s-6)

To 1-chloro-2-nitrobenzene (152 mg, 0.97 mmol, 1.0 equiv.) was addedneat 2-(2-(prop-2-ynyloxy)ethoxy)ethanamine (s-5) (900 mg, 6.31 mmol,6.5 equiv.), and the resulting slurry was heated to 100° C. for 6 hoursduring which time the solid dissolved. At the end of this period, theheating bath was removed, the reaction content was mixed with water (50mL), and then extracted with CH₂Cl₂ (3×50 mL). The organic layers werecombined, dried with Na₂SO₄, concentrated under reduced pressure, andchromatographed (silica gel, 1×25 cm, 0% CH₃OH in CH₂Cl₂, then 10% CH₃OHin CH₂Cl₂) to yield 2-nitro-N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)aniline(s-6) as a dark yellow oil (76 mg, 30%). IR (thin film) 3378 (m), 3286(m), 3085 (w), 2875 (m), 2114 (w), 1616 (s), 1570 (s), 1508 (s), 1417(m), 1349 (m), 1228 (s), 1093 (s), 1034 (m), 740 (m), 670 (s); ¹H NMR(500 MHz, CDCl₃) δ 8.23 (bs, 1H), 8.18 (dd, J=8.6, 1.6 Hz, 1H), 7.43(ddd, J=8.6, 7.0, 1.6 Hz, 1H), 6.86 (d, J=8.6 Hz, 1H), 6.65 (ddd, J=8.3,7.0, 1.2 Hz, 1H), 4.22 (d, J=2.4 Hz, 2H), 3.80 (t, J=5.5 Hz, 2H), 3.73(d, J=2.4 Hz, 4H), 3.52 (q, J=5.4 Hz, 2H), 2.43 (t, J=2.4 Hz, 1H). ¹³CNMR (125 MHz, CDCl₃) δ 145.45, 136.13, 132.22, 126.94, 115.39, 113.78,79.56, 74.61, 70.50, 69.20, 69.19, 58.52, 42.75; HRMS (ES+) calc'd forC₁₃H₁₆N₂O₄ (M+H) m/z 265.1144 Found 265.1181.

4-nitro-N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)aniline (s-7)

To 1-chloro-4-nitrobenzene (152 mg, 0.97 mmol, 1.0 equiv.) was addedneat 2-(2-(prop-2-ynyloxy)ethoxy)ethanamine (s-5) (900 mg, 6.31 mmol,6.5 equiv.), and the resulting slurry was heated to 100° C. for 19hours. At the end of this period, the heating bath was removed, and thereaction content was mixed with water (50 mL) and then extracted withCH₂Cl₂ (3×50 mL). The organic layers were combined, dried with Na₂SO₄,concentrated under reduced pressure, and chromatographed (silica gel,1×25 cm, 0% EtOAc in CH₂Cl₂, then 30% EtOAc in CH₂Cl₂ to yield4-nitro-N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)aniline (s-7) as a darkyellow oil (40 mg, 16%). IR (thin film) 3351 (m), 3239 (m), 2858 (w),2112 (w), 1599 (s), 1535 (w), 1500 (w), 1467 (s), 1284 (s), 1086 (s),1034 (w); ¹H NMR (400 MHz, CDCl₃) δ 8.06 (d, J=9.2 Hz, 2H), 6.53 (d,J=9.2 Hz, 2H), 5.05 (bs, 1H), 4.19 (d, J=2.4 Hz, 2H), 3.76-3.70 (m, 2H),3.70-3.64 (m, 4H), 3.38 (q, J=5.3 Hz, 2H), 2.45 (t, J=2.4 Hz, 1H). ¹³CNMR (125 MHz, CDCl₃) □153.4, 138.0, 126.4, 111.2, 79.5, 74.9, 70.3,69.1, 69.0, 58.5, 42.9. HRMS (ES+) calc'd for C₁₃H₁₆N₂O₄ (M+H) m/z265.1144 Found 265.1177.

N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)aniline (s-9)

2-(2-(prop-2-ynyloxy)ethoxy)ethyl 4-methylbenzenesulfonate (s-8)² (100mg, 0.335 mmol, 0.31 equiv.) was dissolved in aniline (102 mg, 1.10mmol, 1 equiv.). The reaction was allowed to proceed at 100° C. in asealed reaction vessel for 5 hours, after which time it waschromatographed (Silica Gel, 25 g RediSep pre-packed column, 0%EtOAc:Hexanes→20% EtOAc:Hexanes) to yieldN-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)aniline (s-9) as a brown oil (39.0mg, 53.1%). IR (thin film) 3393 (m), 3278 (m), 3052 (w), 2865 (m), 2115(w), 1603 (s), 1506 (s), 1461 (w), 1320 (w), 1277 (m), 1099 (s), 1030(w), 750 (s), 693 (s); ¹H NMR (500 MHz, CDCl₃) δ 7.22-7.16 (m, 2H), 6.72(t, J=7.3 Hz, 1H), 6.67-6.63 (m, 2H), 4.22 (d, J=2.4 Hz, 2H), 4.12 (s,1H), 3.74-3.70 (m, 4H), 3.70-3.66 (m, 2H), 3.32 (t, J=5.2 Hz, 2H), 2.46(t, J=2.4 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃)

148.7, 129.6, 117.9, 113.5, 80.0, 75.1, 70.5, 70.1, 69.5, 58.9, 43.9.HRMS (ES+) calc'd for C₁₃H₁₇NO₂ (M+H) m/z 220.1293 Found 220.1327.

4-methoxy-N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)aniline (s-10)

K₂CO₃ (380 mg, 2.76 mmol, 2.5 equiv.) was added to a solution of4-methoxyaniline (136 mg, 1.1 mmol, 1 equiv.) in 1 mL of DMF, and theresulting slurry was heated to 100° C. 2-(2-(prop-2-ynyloxy)ethoxy)ethyl4-methylbenzenesulfonate (s-8) (100 mg, 0.276 mmol, 0.25 equiv.),dissolved in DMF (1 mL), was then added to the reaction via syringe-pumpover 5 hours. The reaction was stirred for an additional 12 hours, afterwhich time it was concentrated under reduced pressure and partiallypurified (Silica Gel, 12 g RediSep pre-packed column, 0%EtOAc:Hexanes→20% EtOAc:Hexanes→50% EtOAc:Hexanes, followed by EtOAcflush). The material obtained after chromatography was carried directlyon to the next step without further purification.

N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)cyclohexanamine (s-11)

Cyclohexylamine (150 mg, 1.5 mmol, 1 equiv.) and2-(2-(prop-2-ynyloxy)ethoxy)ethyl 4-methylbenzenesulfonate (s-8) (100mg, 0.335 mmol, 0.2 equiv.) were dissolved in 1 mL of ethanol. Thereaction was allowed to proceed under microwave irradiation at 80° C.for 10 minutes, after which it was concentrated under reduced pressureand chromatographed (Silica Gel, 25 g RediSep pre-packed column, 10%EtOAc:Hexanes→50% EtOAc:Hexanes, followed by EtOAc flush) to giveN-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)cyclohexanamine (s-10) as a clearoil (28 mg, 37%). IR (thin film) 3253 (w), 2924 (s), 2852 (s), 2113 (w),1449 (m), 1349 (m), 1263 (w), 1102 (s), 919 (w), 839 (w); ¹H NMR (400MHz, CDCl₃) δ 4.19 (d, J=2.4 Hz, 2H), 3.70-3.65 (m, 2H), 3.65-3.60 (m,2H), 3.59 (t, J=5.4 Hz, 2H), 2.80 (t, J=5.4 Hz, 2H), 2.42 (t, J=2.3 Hz,1H), 2.40-2.34 (m, 1H), 1.90-1.84 (m, 2H), 1.72-1.69 (m, 2H), 1.64-1.54(m, 1H), 1.30-1.15 (m, 3H), 1.15-0.99 (m, 2H), 0.92-0.81 (m, 1H). ¹³CNMR (100 MHz, CDCl₃) δ 79.6, 74.6, 70.9, 70.1, 69.0, 58.4, 56.8, 42.3,33.4, 26.2, 25.1. HRMS (ES+) calc'd for C₁₃H₂₃NO₂ (M+H) m/z 226.1762Found 226.1797.

(S)-2-(3-((S)-1-carboxy-5-(4-((2,4-dinitrophenylamino)methyl)-1H-1,2,3-triazol-1-yl)pentyl)ureido)pentanedioicacid (1)

2,4-dinitro-N-(prop-2-ynyl)aniline³ (48.75 mg, 0.220 mmol, 1.1 equiv.)and azide s-12⁴ (100 mg, 0.194 mmol, 1 equiv.) were added to a mixtureof water (0.694 mL) and t-BuOH (0.694 mL). The slurry was placed in amicrowave reaction tube, to which a 0.1 M solution of sodium ascorbatein water (0.388 mL, 0.039 mmol, 0.2 equiv.) and a 0.1 M solution ofcopper (II) sulfate in water (0.078 mL, 0.008 mmol, 0.04 equiv.) wereadded. The tube was capped and subjected to microwave irradiation at110° C. for 20 minutes. The crude mixture was concentrated under reducedpressure, and taken up in 67% trifluoroacetic acid in CH₂Cl₂ (3 mL). Thetube was capped and subjected to microwave irradiation at 70° C. for 2minutes. The crude mixture was concentrated under reduced pressure,purified via HPLC, and the pure fractions were collected andconcentrated under reduced pressure to yield 1 (47.7 mg, 43.6% over twosteps) as a yellow solid. IR (thin film) 3367 (br), 2946 (br), 1720 (m),1619 (s), 1589 (m), 1524 (w), 1425 (w), 1338 (m), 1203 (m), 1137 (m); ¹HNMR (400 MHz, MeOD) δ 9.05 (d, J=2.6 Hz, 1H), 8.29 (dd, J=9.5, 2.6 Hz,1H), 8.00 (s, 1H), 7.24 (d, J=9.6 Hz, 1H), 4.82 (s, 2H), 4.41 (t, J=7.0Hz, 2H), 4.29 (ddd, J=18.6, 8.5, 4.9 Hz, 2H), 2.50-2.33 (m, 2H),2.20-2.10 (m, 1H), 2.03-1.80 (m, 4H), 1.72-1.62 (m, 1H), 1.48-1.36 (m,2H). ¹³CNMR (125 MHz, DMSO-d₆)

174.3, 174.1, 173.7, 157.2, 147.8, 143.1, 135.2, 130.1, 130.0, 123.5,123.0, 115.7, 52.0, 51.5, 49.3, 38.4, 29.8, 29.4, 27.4, 22.1. HRMS (ES+)calc'd for C₂₁H₂₆N₈O₁₁ (M+H) m/z 567.1755 Found 567.1796.

(S)-2-(3-((S)-1-carboxy-5-(4-((2-(2,4-dinitrophenylamino)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)pentyl)ureido)pentanedioicacid (2)

2,4-dinitro-N-(2-(prop-2-ynyloxy)ethyl)aniline (s-2a) (51.4 mg, 0.194mmol, 1 equiv.) and azide s-12 (100 mg, 0.194 mmol, 1 equiv.) were addedto a mixture of water (0.694 mL) and t-BuOH (0.694 mL). This slurry wasplaced in a microwave reaction tube, to which a 0.1 M solution of sodiumascorbate in water (0.388 mL, 0.039 mmol, 0.2 equiv.) and 0.1 M solutionof copper (II) sulfate in water (0.078 mL, 0.008 mmol, 0.04 equiv.) wereadded. The tube was capped and subjected to microwave irradiation at110° C. for 20 minutes. The crude mixture was concentrated under reducedpressure, and taken up in 67% trifluoroacetic acid in CH₂Cl₂ (3 mL). Thetube was capped and subjected to microwave irradiation at 70° C. for 2minutes. The crude mixture was concentrated under reduced pressure,purified via HPLC, and the pure fractions were collected andconcentrated under reduced pressure to yield 2 (38.0 mg, 32.2% over twosteps), as a yellow oil. IR (thin film) 3356 (m), 2938 (m), 1731 (s),1621 (s), 1586 (m), 1525 (m), 1426 (w), 1336 (s), 1306 (w), 1137 (w),1087 (m), 833 (w); ¹H NMR (500 MHz, MeOD) δ 9.00 (d, J=2.2 Hz, 1H), 8.25(dd, J=9.6, 2.3 Hz, 1H), 7.98 (s, 1H), 7.18 (d, J=9.6 Hz, 1H), 4.68 (s,2H), 4.41 (t, J=6.9 Hz, 2H), 4.28 (ddd, J=18.1, 8.2, 5.0 Hz, 2H), 3.82(t, J=5.0 Hz, 2H), 3.67 (t, J=5.0 Hz, 2H), 2.48-2.33 (m, 2H), 2.17-2.10(m, 1H), 2.01-1.81 (m, 4H), 1.71-1.64 (m, 1H), 1.46-1.35 (m, 2H). ¹³CNMR(125 MHz, DMSO-d₆)

174.4, 174.1, 173.7, 157.2, 148.3, 143.6, 134.9, 129.9, 129.7, 123.8,123.6, 115.6, 67.3, 63.4, 52.1, 51.6, 49.1, 42.6, 31.5, 29.9, 29.4,27.5, 22.1. HRMS (ES+) calc'd for C₂₃H₃₀N₈O₁₂ (M+H) m/z 611.2017 Found611.2074.

(S)-2-(3-((S)-1-carboxy-5-(4-((2-(2-(2,4-dinitrophenylamino)ethoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)pentyl)ureido)pentanedioicacid (3)

2,4-dinitro-N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)aniline (s-2b) (60 mg,0.194 mmol, 1 equiv.) and azide s-12 (100 mg, 0.194 mmol, 1 equiv.) wereadded to a mixture of water (0.694 mL) and t-BuOH (0.694 mL). Thisslurry was placed in a microwave reaction tube, to which a 0.1 Msolution of sodium ascorbate in water (0.388 mL, 0.039 mmol, 0.2 equiv.)and 0.1 M solution of copper (II) sulfate in water (0.078 mL, 0.008mmol, 0.04 equiv.) were added. The tube was capped and subjected tomicrowave irradiation at 110° C. for 20 minutes. The crude mixture wasconcentrated under reduced pressure, and taken up in 67% trifluoroaceticacid in CH₂Cl₂ (3 mL). The tube was capped and subjected to microwaveirradiation at 70° C. for 2 minutes. The crude mixture was concentratedunder reduced pressure, purified via HPLC, and the pure fractions werecollected and concentrated under reduced pressure to yield 3(31.0 mg,24.6% over two steps) as a yellow oil. IR (thin film) 3360 (m), 2933(m), 1726 (s), 1621 (s), 1587 (m), 1525 (w), 1425 (w), 1337 (s), 1306m), 1136 (m); ¹H NMR (400 MHz, MeOD) □ 9.01 (d, J=2.7 Hz, 1H), 8.26 (dd,J=9.6 Hz, 2.7 Hz, 1H), 7.97 (s, 1H), 7.20 (d, J=9.6 Hz, 1H), 4.63 (s,2H), 4.41 (t, J=7.0 Hz, 2H), 4.33-4.23 (m, 2H), 3.80 (t, J=5.2 Hz, 2H),3.72-3.68 (m, 4H), 3.66 (t, J=5.2, 2H), 2.48-2.32 (m, 2H), 2.19-2.08 (m,1H), 2.00-1.80 (m, 4H), 1.73-163 (m, 1H), 1.46-1.35 (m, 2H). ¹³CNMR (125MHz, DMSO-d₆) □ 174.3, 174.1, 173.6, 157.2, 148.2, 143.8, 134.9, 129.9,129.6, 123.6, 115.6, 69.7, 68.9, 68.2, 63.6, 52.0, 51.5, 49.1, 42.5,31.4, 29.8, 29.4, 27.4, 22.1. HRMS (ES+) calc'd for C₂₅H₃₄N₈O₁₃ (M+H)m/z 655.2279 Found 655.2275.

2,5,8,11,14,17,20,23,26,29,32,35,38-tridecaoxahentetracont-40-yne(s-13e)

2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaheptatriacontan-37-ol (150 mg,22.89 mmol, 1.0 equiv.) was slowly added to a slurry of NaH (48 mg,45.78 mol, 8 equiv.) in DMF (1.4 mL) in a flame dried flask pre-cooledto 0° C. 80% propargyl bromide in toluene (36 □L, 27.47 mmol, 1.2equiv.), cooled to 0° C., was added slowly. The ice bath was removed andthe reaction was allowed to stir at room temperature for an additional 2hours. The reaction was then re-cooled to 0° C., 0.5 mL of ice coldwater was added, and the reaction was concentrated under reducedpressure. The remaining residue was redissolved in dichloromethane, thenpartially purified via silica gel chromatography (10% MeOH in DCM) toremove all the salts. After partial purification,2,5,8,11,14,17,20,23,26,29,32,35,38-tridecaoxahentetracont-40-yne(s-13e) was obtained as a brown oil that was taken on to the next stepwithout full purification.

(S)-2-(3-((S)-1-carboxy-5-(4-(methoxymethyl)-1H-1,2,3-triazol-1-yl)pentyl)ureido)pentanedioicacid (8)

Methyl propargyl ether (s-13a) (81.8 mg, 1.16 mmol, 6 equiv.) and azides-12 (100 mg, 0.194 mmol, 1 equiv.) were added to a mixture of water(0.694 mL) and t-BuOH (0.694 mL). This slurry was placed in a microwavereaction tube to which 0.1 M solution of sodium ascorbate in water(0.388 mL, 0.039 mmol, 0.2 equiv.) and 0.1 M solution of copper (II)sulfate in water (0.078 mL, 0.008 mmol, 0.04 equiv.) were added. Thetube was capped and subjected to microwave irradiation at 110° C. for 20minutes. The crude mixture was concentrated under reduced pressure, andtaken up in 67% trifluoroacetic acid in CH₂Cl₂ (3 mL). The tube wascapped and subjected to microwave irradiation at 70° C. for 2 minutes.The crude mixture was concentrated under reduced pressure, purified viaHPLC, and the pure fractions were collected and concentrated underreduced pressure to yield 8(32.9 mg, 41.4% over two steps) as a clearoil. IR (thin film) 3368 (br), 2936 (m), 1670 (s), 1564 (m), 1437 (w),1193 (s), 1139 (s), 1064 (m), 839 (w), 800 (w), 723 (w). ¹H NMR (500MHz, MeOD) δ 8.00 (s, 1H), 4.55 (s, 2H), 4.43 (t, J=7.0 Hz, 2H),4.36-4.25 (m, 2H), 3.38 (s, 3H), 3.18 (s, 0H), 2.48-2.35 (m, 2H),2.19-2.12 (m, 1H), 2.02-1.82 (m, 4H), 1.75-1.64 (m, 1H), 1.48-1.36 (m,2H). ¹³CNMR (125 MHz, MeOD)

176.5, 176.2, 175.8, 160.1, 145.6, 125.2, 66.2, 58.4, 53.7, 53.5, 51.3,32.8, 31.1, 30.7, 28.8, 23.4. HRMS (ES+) calc'd for C₁₆H₂₅N₅O₈ (M+H) m/z416.1737 Found 415.2019.

(S)-2-(3-((S)-1-carboxy-5-(4-((2-(2-methoxyethoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)pentyl)ureido)pentanedioicacid (9)

3-(2-(2-methoxyethoxy)ethoxy)prop-1-yne (s-13b)⁵ (30.7 mg, 0.194 mmol, 1equiv.) and azide s-12 (100 mg, 0.194 mmol, 1 equiv.) were added to amixture of water (0.694 mL) and t-BuOH (0.694 mL). This slurry wasplaced in a microwave reaction tube, to which a 0.1 M solution of sodiumascorbate in water (0.388 mL, 0.039 mmol, 0.2 equiv.) and 0.1 M solutionof copper (II) sulfate in water (0.078 mL, 0.008 mmol, 0.04 equiv.) wereadded. The tube was capped and subjected to microwave irradiation at110° C. for 20 minutes. The crude mixture was concentrated under reducedpressure, and taken up in 67% trifluoroacetic acid in CH₂Cl₂ (3 mL). Thetube was capped and subjected to microwave irradiation at 70° C. for 2minutes. The crude mixture was concentrated under reduced pressure,purified via HPLC, and the pure fractions were collected andconcentrated under reduced pressure to yield 9 (30.6 mg, 31.5% over twosteps) as a clear oil, IR (thin film) 3346 (br), 2931 (m), 1734 (s),1642 (m), 1562 (s), 1451 (w), 1201 (s), 1087 (s); ¹H NMR (400 MHz, MeOD)δ 8.01 (s, 1H), 4.65 (s, 2H), 4.43 (t, J=7.0 Hz, 2H), 4.33-4.24 (m, 2H),3.69-3.64 (m, 4H), 3.64-3.60 (m, 2H), 3.56-3.49 (m, 2H), 3.33 (s, 3H),2.46-2.34 (m, 2H), 2.16-2.11 (m, 1H), 2.00-1.82 (m, 4H), 1.71-1.64 (m,1H), 1.48-1.31 (m, 2H). ¹³CNMR (125 MHz, CD₃OD) □ 176.4, 176.1, 175.8,160.1, 145.8, 125.3, 72.9, 71.5, 71.3, 70.8, 64.8, 59.1, 53.7, 53.5,51.3, 32.8, 31.1, 30.7, 28.8, 23.4. HRMS (ES+) calc'd for C₂₀H₃₃N₅O₁₀(M+H) m/z 504.2261 Found 504.2590.

(S)-2-(3-((S)-5-(4-2,5,8,11,14-pentaoxapentadecyl-1H-1,2,3-triazol-1-yl)-1-carboxypentyl)ureido)pentanedioicacid (10)

2,5,8,11,14-pentaoxaheptadec-16-yne (s-13d)⁵ (52 mg, 0.194 mmol, 1equiv.) and azide s-12 (100 mg, 0.194 mmol, 1 equiv.) were added to amixture of water (0.694 mL) and t-BuOH (0.694 mL). This slurry wasplaced in a microwave reaction tube, to which a 0.1 M solution of sodiumascorbate in water (0.388 mL, 0.039 mmol, 0.2 equiv.) and 0.1 M solutionof copper (II) sulfate in water (0.078 mL, 0.008 mmol, 0.04 equiv.) wereadded. The tube was capped and subjected to microwave irradiation at110° C. for 20 minutes. The crude mixture was concentrated under reducedpressure, and taken up in 67% trifluoroacetic acid in CH₂Cl₂ (3 mL). Thetube was capped and subjected to microwave irradiation at 70° C. for 2minutes. The crude mixture was concentrated under reduced pressure,purified via HPLC, and the pure fractions were collected andconcentrated under reduced pressure to yield 10 (19.8 mg, 15.9% over twosteps) as a clear oil. IR (thin film) 3323 (br), 2921 (m), 1734 (s),1642 (w), 1562 (m), 1452 (w), 1201 (m), 1089 (m), 845 (w); ¹H NMR (500MHz, MeOD) δ 8.04 (s, 1H), 4.65 (s, 2H), 4.44 (t, J=7.0 Hz, 2H),4.34-4.24 (m, 2H), 3.70-3.65 (m, 4H), 3.65-3.58 (m, 12H), 3.52 (dd,J=5.6, 3.6 Hz, 2H), 3.34 (s, 3H), 2.47-2.35 (m, 2H), 2.19-2.09 (m, 1H),2.02-1.82 (m, 4H), 1.72-1.65 (m, 1H), 1.45-1.36 (m, 2H). ¹³CNMR (125MHz, DMSO-d₆)

176.4, 176.1, 160.1, 145.7, 125.3, 72.9, 71.5, 71.3, 70.8, 64.8, 59.1,53.7, 53.5, 51.3, 32.8, 31.1, 30.7, 28.8, 23.4. HRMS (ES+) calc'd forC₂₄H₄₁N₅O₁₂ (M+H) m/z 592.2785 Found 592.2783.

(S)-2-(3-((S)-5-(4-2,5,8,11,14,17,20,23,26-nonaoxaheptacosyl-1H-1,2,3-triazol-1-yl)-1-carboxypentyl)ureido)pentanedioicacid (11)

2,5,8,11,14,17,20,23,26-nonaoxanonacos-28-yne (s-13d)⁶ (41 mg, 0.097mmol, 1 equiv.) and azide s-12 (50 mg, 0.097 mmol, 1 equiv.) were addedto a mixture of water (0.350 mL) and t-BuOH (0.350 mL). This slurry wasplaced in a microwave reaction tube, to which a 0.1 M solution of sodiumascorbate in water (0.194 mL, 0.019 mmol, 0.2 equiv.) and 0.1 M solutionof copper (II) sulfate in water (0.039 mL, 0.004 mmol, 0.04 equiv.) wereadded. The tube was capped and subjected to microwave irradiation at110° C. for 20 minutes. The crude mixture was concentrated under reducedpressure, and taken up in 67% trifluoroacetic acid in CH₂Cl₂ (3 mL). Thetube was capped and subjected to microwave irradiation at 70° C. for 2minutes. The crude mixture was concentrated under reduced pressure,purified via HPLC, and the pure fractions were collected andconcentrated under reduced pressure to yield 11 (9.6 mg, 21.4% over twosteps) as a clear oil. IR (thin film) 3332 (br), 2919 (m), 2875 (m),1734 (s), 1557 (m), 1452 (w), 1203 (s), 1088 (s), 946 (w), 850 (w); ¹HNMR (400 MHz, MeOD) δ 8.00 (s, 1H), 4.64 (s, 2H), 4.42 (t, J=6.9 Hz,2H), 4.35-4.23 (m, 2H), 3.66 (s, 4H), 3.62 (m, J=5.5, 1.1 Hz, 26H),3.56-3.52 (m, 2H), 3.36 (d, J=1.1 Hz, 3H), 2.45-2.41 (m, 2H), 2.22-2.07(m, 1H), 1.98-1.82 (m, 4H), 1.72-1.64 (m, 1H), 1.44-1.35 (m, 2H), ¹³CNMR(125 MHz, MeOD)

176.4, 176.1, 175.8, 160.1, 145.9, 125.2, 73.0, 71.5, 71.3, 70.8, 64.9,59.1, 53.7, 53.5, 51.2, 32.8, 31.1, 30.7, 28.8, 23.4. HRMS (ES+) calc'dfor C₃₂H₅₇N₅O₁₆ (M+H) m/z 768.3834 Found 768.3865.

(S)-2-(3-((S)-5-(4-2,5,8,11,14,17,20,23,26,29,32,35,38-tridecaoxanonatriacontyl-1H-1,2,3-triazol-1-yl)-1-carboxypentyl)ureido)pentanedioicacid (12)

Crude 2,5,8,11,14,17,20,23,26,29,32,35,38-tridecaoxahentetracont-40-yne(s-13e) (58 mg, 0.097 mmol, 1 equiv.) and azide s-12 (50 mg, 0.097 mmol,1 equiv.) were added to a mixture of water (0.350 mL) and t-BuOH (0.350mL). This slurry was placed in a microwave reaction tube, to which a 0.1M solution of sodium ascorbate in water (0.194 mL, 0.019 mmol, 0.2equiv.) and 0.1 M solution of copper (II) sulfate in water (0.039 mL,0.004 mmol, 0.04 equiv.) were added. The tube was capped and subjectedto microwave irradiation at 110° C. for 20 minutes. The crude mixturewas concentrated under reduced pressure, and taken up in 67%trifluoroacetic acid in CH₂Cl₂ (3 mL). The tube was capped and subjectedto microwave irradiation at 70° C. for 2 minutes. The crude mixture wasconcentrated under reduced pressure, purified via HPLC, and the purefractions were collected and concentrated under reduced pressure toyield 12 (13.0 mg, 9.6%, 3 steps) as a clear oil. IR (thin film) 3369(br), 2878 (s), 1673 (s), 1561 (w), 1456 (w), 1351 (w), 1200 (s), 1105(s), 950 (w), 836 (w), 800 (w), 721 (w); ¹H NMR (500 MHz, MeOD) δ 8.00(s, 1H), 4.64 (s, 2H), 4.42 (t, J=7.0 Hz, 2H), 4.33-4.24 (m, 2H),3.69-3.59 (m, 46H), 3.56-3.52 (m, 2H), 2.48-2.34 (m, 2H), 2.19-2.09 (m,1H), 2.02-1.81 (m, 4H), 1.71-1.64 (m, 1H), 1.45-1.33 (m, 2H). ¹³CNMR(125 MHz, MeOD)

176.4, 176.1, 175.8, 160.1, 145.9, 125.2, 72.9, 71.5, 71.3, 70.7, 65.0,59.1, 53.7, 53.5, 51.1, 32.9, 31.1, 30.8, 28.9, 23.4. LCMS (ES+) calc'dfor C₄₀H₇₃N₅O₂₀ (M+H) m/z 944.49 Found 944.72,

(S)-2-(3-((S)-1-carboxy-5-(4-((2-(2-(2-nitrophenylamino)ethoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)pentyl)ureido)pentanedioicacid (13)

2-nitro-N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)aniline (s-6) (51.2 mg,0.194 mmol, 1 equiv.) and azide s-12 (100 mg, 0.194 mmol, 1 equiv.) wereadded to a mixture of water (0.694 mL) and t-BuOH (0.694 mL). Thisslurry was placed in a microwave reaction tube, to which a 0.1 Msolution of sodium ascorbate in water (0.388 mL, 0.039 mmol, 0.2 equiv.)and 0.1 M solution of copper (II) sulfate in water (0.078 mL, 0.008mmol, 0.04 equiv.) were added. The tube was capped and subjected tomicrowave irradiation at 110° C. for 20 minutes. The crude mixture wasconcentrated under reduced pressure, and taken up in 67% trifluoroaceticacid in CH₂Cl₂ (3 mL). The tube was capped and subjected to microwaveirradiation at 70° C. for 2 minutes. The crude mixture was concentratedunder reduced pressure, purified via HPLC, and the pure fractions werecollected and concentrated under reduced pressure to yield 13 (36.5 mg,31.0% over two steps) as a dark yellow oil. IR (thin film) 3335 (br),2923 (m), 1722 (s), 1668 (m), 1602 (s), 1561 (w), 1470 (w), 1308 (s),1187 (m), 1111 (w), 998 (w), 836 (w); ¹H NMR (500 MHz, MeOD) δ 8.12 (dd,J=8.6, 1.6 Hz, 1H), 7.98 (s, 1H), 7.49 (ddd, J=8.6, 6.9, 1.6 Hz, 1H),7.02 (dd, J=8.7, 0.9 Hz, 1H), 6.67 (ddd, J=8.3, 6.9, 1.2 Hz, 1H), 4.65(s, 2H), 4.41 (t, J=7.1 Hz, 2H), 4.30 (ddd, J=17.8, 8.4, 5.0 Hz, 2H),3.78 (t, J=5.3 Hz, 2H), 3.71 (m, 4H), 3.53 (t, J=5.3 Hz, 2H), 2.44-2.40(m, 2H), 2.21-2.10 (m, 1H), 2.00-1.81 (m, 4H), 1.72-1.65 (m, 1H),1.47-1.35 (m, 2H). ¹³CNMR (125 MHz, DMSO-d₆) □ 174.4, 174.1, 173.7,157.2, 145.2, 143.9, 136.6, 131.0, 126.2, 123.6, 115.4, 114.7, 69.6,68.9, 68.4, 63.6, 52.1, 51.6, 49.1, 42.0, 31.5, 29.9, 29.4, 27.5, 22.1.HRMS (ES+) calc'd for C₂₅H₃₅N₇O₁₁ (M+H) m/z 610.2428 Found 610.2471.

(S)-2-(3-((S)-1-carboxy-5-(4-((2-(2-(4-nitrophenylamino)ethoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)pentyl)ureido)pentanedioicacid (14)

4-nitro-N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)aniline (s-7) (34.2 mg,0.129 mmol, 1 equiv.) and azide s-12 (66.7 mg, 0.129 mmol, 1 equiv.)were added to a mixture of water (0.600 mL) and t-BuOH (0.600 mL). Thisslurry was placed in a microwave reaction tube, to which a 0.1 Msolution of sodium ascorbate in water (0.260 mL, 0.026 mmol, 0.2 equiv.)and a 0.1 M solution of copper (II) sulfate in water (0.051 mL, 0.005mmol, 0.04 equiv.) were added. The tube was capped and subjected tomicrowave irradiation at 110° C. for 20 minutes. The crude mixture wasconcentrated under reduced pressure, and taken up in 67% trifluoroaceticacid in CH₂Cl₂ (3 mL). The tube was capped and subjected to microwaveradiation at 70° C. for 2 minutes. The crude mixture was concentratedunder reduced pressure, purified via HPLC, and the pure fractions werecollected and concentrated under reduced pressure to yield 14 (21.7 mg,27.6% over two steps) as a yellow oil. IR (thin film) 3335 (br), 2924(m), 2870 (m), 1722 (s), 1668 (m), 1602 (s), 1561 (m), 1505 (w), 1470(w), 1308 (s), 1187 (m), 1118 (m), 837 (w); ¹H NMR (500 MHz, MeOD) δ8.01 (d, J=10.4 Hz, 1H), 7.95 (s, 1H), 6.64 (d, J=10.4 Hz, 1H) 4.63 (s,2H), 4.39 (t, J=7.0 Hz, 2H), 4.29 (ddd, J=16.4, 8.4, 5.0 Hz, 2H),3.71-3.62 (m, 6H), 3.38 (t, J=5.4 Hz, 2H), 2.47-2.34 (m, 2H), 2.19-2.08(m, 1H), 1.99-1.80 (m, 4H), 1.71-1.64 (m, 1H), 1.42-1.36 (m, 2H). ¹³CNMR(125 MHz, DMSO-d₆) □ 174.4, 174.1, 173.7, 157.3, 154.6, 143.8, 135.6,126.2, 123.7, 110.8, 69.6, 68.9, 68.6, 63.5, 52.1, 51.6, 49.1, 42.3,31.5, 29.9, 29.4, 27.5, 22.1. HRMS (ES+) calc'd for C₂₅H₃₅N₇O₁₁ (M+H)m/z 610.2428 Found 610.2468.

(S)-2-(3-((S)-1-carboxy-5-(4-((2-(2-(phenylamino)ethoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)pentyl)ureido)pentanedioicacid (15)

N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)aniline (s-9) (35 mg, 0.160 mmol, 1equiv.) and azide 31 (82 mg, 0.160 mmol, 1 equiv.) were added to amixture of water (1 mL) and t-BuOH (1 mL). This slurry was placed in amicrowave reaction tube, to which a 0.1 M solution of sodium ascorbatein water (7.8 mg, 0.04 mmol, 0.25 equiv.) and a 0.1 M solution of copper(II) sulfate in water (0.080 mL, 0.008 mmol, 0.05 equiv.) were added.The tube was capped and subjected to microwave irradiation at 110° C.for 20 minutes. The crude mixture was concentrated under reducedpressure, and taken up in 67% trifluoroacetic acid in CH₂Cl₂ (3 mL). Thetube was capped and subjected to microwave irradiation at 70° C. for 2minutes. The crude mixture was concentrated under reduced pressure,purified via HPLC, and the pure fractions were collected andconcentrated under reduced pressure to yield 15 (13.7 mg, 15.3% over twosteps) as a light brown oil. IR (thin film) 3369 (br), 2939 (m), 1664(s), 1563 (m), 1497 (w), 1438 (w), 1188 (s), 1134 (s), 837 (w), 798 (w),753 (w), 721 (w); ¹H NMR (400 MHz, MeOD) δ 8.02 (s, 1H), 7.58-7.49 (m,5H), 4.64 (s, 2H), 4.37 (t, J=7.0 Hz, 2H), 4.33-4.24 (m, 2H), 3.70-3.63(m, 6H), 3.27 (t, J=5.4 Hz, 2H), 2.46-2.34 (m, 2H), 2.19-2.08 (m, 1H),1.98-1.79 (m, 4H), 1.71-1.62 (m, 1H), 1.44-1.32 (m, 2H). ¹³CNMR (125MHz, DMSO-d₆) □ 174.4, 174.1, 173.7, 157.3, 146.2, 143.8, 129.1, 123.7,118.3, 114.2, 69.6, 68.9, 68.2, 63.6, 52.1, 51.7, 49.1, 44.1, 31.5,29.9, 29.4, 27.5, 22.1, HRMS (ES+) calc'd for C₂₅H₃₆N₆O₉ (M+H) m/z565.2577 Found 565.2621.

(S)-2-(3-((S)-1-carboxy-5-(4-((2-(2-(4-methoxyphenylamino)ethoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)pentyl)ureido)pentanedioicacid (16)

4-methoxy-N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)aniline (s-10) (34 mg,0.137 mmol, 1 equiv.) and azide s-12 (70 mg, 0.137 mmol, 1 equiv.) wereadded to a mixture of water (1 mL) and t-BuOH (1 mL). This slurry wasplaced in a microwave reaction tube, to which a 0.1 M solution of sodiumascorbate (6 mg, 0.034 mmol, 0.25 equiv.) and a 0.1 M solution of copper(II) sulfate in water (0.068 mL, 0.007 mmol, 0.05 equiv.) were added.The tube was capped and subjected to microwave irradiation at 110° C.for 20 minutes. The crude mixture was concentrated under reducedpressure, and taken up in 67% trifluoroacetic acid in CH₂Cl₂ (3 mL). Thetube was capped and subjected to microwave irradiation at 70° C. for 2minutes. The crude mixture was concentrated under reduced pressure,purified via HPLC, and the pure fractions were collected andconcentrated under reduced pressure to yield 16 (9.3 mg, 11.8% overthree steps) as a light brown oil. IR (thin film) 3347 (br), 2956 (m),1728 (s), 1670 (s), 1564 (m), 1513 (m), 1443 (w), 1259 (w), 1200 (s),1137 (m), 1029 (w), 837 (w); ¹H NMR (400 MHz, MeOD) δ 8.01 (s, 1H),7.45-7.39 (m, 2H), 7.09-7.04 (m, 2H), 4.68 (s, 2H), 4.42 (t, J=7.0 Hz,2H), 4.30 (dd, J=8.6, 5.0 Hz, 1H), 4.22 (dd, J=8.5, 4.9 Hz, 1H), 3.87(s, 3H), 3.75-3.73 (m, 2H), 3.72-3.68 (m, 2H), 3.68-3.64 (m, 2H),3.57-3.50 (m, 2H), 2.49-2.33 (m, 2H), 2.17-2.12 (m, 1H), 2.01-1.79 (m,4H), 1.72-1.57 (m, 1H), 1.45-1.32 (m, 2H). ¹³CNMR (125 MHz, DMSO-d₆)

174.4, 174.1, 173.7, 157.2, 143.7, 126.5, 123.7, 121.6, 117.4, 114.9,69.7, 68.8, 65.9, 63.5, 55.4, 52.1, 51.6, 49.1, 48.4, 31.5, 29.9, 29.4,27.5, 22.{tilde over (1)} HRMS (ES+) calc'd for C₂₆H₃₈N₆O₁₀ (M+H) m/z595.2683 Found 595.2722.

(S)-2-(3-((S)-1-carboxy-5-(4-((2-(2-(cyclohexylamino)ethoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)pentyl)ureido)pentanedioicacid (17)

N-(2-(2-(prop-2-ynyloxy)ethoxy)ethyl)cyclohexanamine (s-11) (16 mg,0.071 mmol, 1 equiv.) and azide s-12 (16 mg, 0.071 mmol, 1 equiv.) wereadded to a mixture of water (0.500 mL) and t-BuOH (0.500 mL). Thisslurry was placed in a microwave reaction tube, to which a 0.1 Msolution of sodium ascorbate in water (3.4 mg, 0.018 mol, 0.25 equiv.)and a 0.1 M solution of copper (II) sulfate in water (0.0355 mL, 0.00355mmol, 0.05 equiv.) were added. The tube was capped and subjected tomicrowave irradiation at 110° C. for 20 minutes. The crude mixture wasconcentrated, and taken up in 67% trifluoroacetic acid in CH₂Cl₂ (3 mL).The tube was capped and subjected to microwave irradiation at 70° C. for2 minutes. The crude mixture was concentrated under reduced pressure,purified via HPLC, and the pure fractions were collected andconcentrated under reduced pressure to yield 17 (7.9 mg, 19.7% over twosteps) as a clear oil. IR (thin film) 3344 (w), 2939 (m), 2865 (w), 1732(m), 1670 (s), 1453 (w), 1201 (s), 1136 (m), 1088 (w), 799 (w); ¹H NMR(400 MHz, MeOD) δ 8.02 (s, 1H), 4.65 (s, 2H), 4.43 (t, J=7.0 Hz, 2H),4.34-4.21 (m, 3H), 3.76-3.64 (m, 7H), 3.26-3.19 (m, 2H), 3.08 (s, 1H),2.50-2.34 (m, 2H), 2.16-2.10 (m, 3H), 2.03-1.81 (m, 6H), 1.70-1.63 (m,2H), 1.46-1.28 (m, 7H), 1.28-1.14 (m, 1H). ¹³CNMR (125 MHz, DMSO-d₆)

174.2, 173.9, 173.5, 157.1, 143.7, 123.7, 69.7, 69.5, 68.7, 68.3, 65.8,63.4, 56.0, 49.1, 43.1, 31.4, 29.8, 29.3, 28.3, 27.4, 24.6, 23.8, 22.1.HRMS (ES+) calc'd for C₂₅H₄₂N₆O₉ (M+H) m/z 571.3047 Found 571.3091.Biological Assays and Crystallographic DataMeasurement of PSMA K_(m):

A 10 mM solution of N-acetyl-aspartylglutamate (NAAG) in 40 mM NaOH, andwas then diluted in Reaction Buffer (100 mM Tris-HCl, pH 7.5) to a finalNAAG concentration of 40 □M. The solution was added to a 384 well plate(20 □L per well). For K_(m) measurements and controls the NAAG solutionwas serially diluted 2-fold in Reaction Buffer to obtain final NAAGconcentrations ranging from 40 □M-312.5 nM. rhPSMA (20 ng/mL in ReactionBuffer, 20 □L, R&D Research) was then added to each well. ReactionBuffer (20 □L) was added to the K_(m) control series. The plate wasincubated at room temperature for 15 min, and then heated to 95° C. for3 minutes. The plate was allowed to cool to room temperature, andglutamic acid levels were measured using a commercially availableAmplex®-Red Glutamic Acid/Glutamate Oxidase Assay Kit (Invitrogen).Fluorescence intensities were measured using a Synergy 2 multiwell platereader (Biotek), fitted with excitation and emission filters of 545 nmand 590 nm, respectively. The K_(m) was calculated using nonlinearleast-squares regression algorithms contained in the GraphPad Prismsoftware package to provide an average K_(m) value for this enzymaticreaction of 0.925 μM. This value is consistent with that reported in theliterature⁷ and was employed in subsequent K_(i) calculations (seebelow).

PSMA Inhibition Assay:

For IC₅₀ measurements, inhibitors were dissolved in Reaction Buffercontaining 40 μM NAAG to a final volume of 100 μL. Then, 25 μL of thissolution was transferred to each of three wells in a microtiter plate,and 5 μL aliquots were serially diluted into 20 μL of solutioncontaining 40 μM NAAG over 10 wells (5-fold dilutions). Inhibitorconcentration therefore ranged over 6 orders of magnitude in theseexperiments. rhPSMA (20 ng/mL in Reaction Buffer, 20 μL, R&D Research)was then added to each well. The plate was incubated at room temperaturefor 15 min, and then heated to 95° C. for 3 minutes. The plate wasallowed to cool to room temperature, and glutamic acid levels weremeasured using a commercially available Amplex®-Red GlutamicAcid/Glutamate Oxidase Assay Kit (Invitrogen). Fluorescence intensitieswere measured using a Synergy 2 multiwell plate reader (Biotek), fittedwith excitation and emission filters of 545 nm and 590 nm, respectively.The concentration of inhibitors giving 50% inhibition of enzyme activity(IC₅₀) was calculated from the least-squares regression line of theresidual enzymatic activity plotted as a function of logarithmicinhibitor concentrations using algorithms contained in the GraphPadPrism software package. K_(i) values were obtained from IC₅₀ valuesusing the Cheng-Prusoff equation, a substrate concentration of 20 μM,and a K_(m) value of 0.925 μM. All reported values in Tables 1 and 2represent the average of at least three replicates±standard deviation.

rhPSMA Expression and Purification

The extracellular domain of human PSMA (amino acids 44-750) wasexpressed and purified as described previously and we designate thisconstruct rhPSMA⁸. For crystallization experiments, rhPSMA was dialyzedagainst 20 mM MOPS, 20 mM NaCl, pH 7.4, and concentrated to 10 mg/mL.

Crystallization, Data Collection and Processing

The stock solutions of individual inhibitors at 50 mM were prepared in25% (v/v) acetonitrile in water. Diffraction quality crystals ofrhPSMA/ARMs complexes were grown at 293 K by vapor diffusion in hangingdrops. The stock solution of rhPSMA was mixed in a 10:1 ratio with anARM and hanging drops formed by mixing equal volumes of the protein andreservoir solutions (33% (v/v) pentaerythritol propoxylate PO/OH 5/4(Hampton Research), 0.5% (w/v) PEG 3350, and 100 mM Tris-HCl, pH 8.0).Prior to the data collection, the crystals were flash-frozen in liquidnitrogen directly from the hanging drop. Each of the four datasets wascollected from a single crystal at 100 K using synchrotron radiation atthe SER-CAT sector 22 beamlines of the Advanced Photon Source (Argonne,Ill., USA) equipped with MAR225 or MAR300CCD detectors. Data wereintegrated and scaled with the HKL2000 package⁹.

Electron Map Density Fit

Individual compounds were fit into the positive electron density in thefinal stages of the refinement. For all four inhibitors, clearinterpretable densities were observed for the C-terminal partencompassing the P1′ glutarate, the urea linkage, the lysine linker, andthe triazole ring

Structure Solution and Refinement

Structure determination of rhPSMA/ARMs complexes was carried out usingdifference Fourier methods with the ligand-free rhPSMA (PDB code2OOT;¹⁰) as a starting model. Calculations were performed with theprogram Refmac 5.1¹¹, and the refinement protocol was interspersed withmanual corrections to the model employing the program Coot¹². Libraryand PDB-format files of individual inhibitors were prepared using thePRODRG server¹³ and the inhibitors were fitted into the positiveelectron density map in the final stages of the refinement. During therefinement process, ˜1% of the randomly selected reflections were keptaside for cross-validation (R_(free)). The quality of the final modelwas evaluated using the MOLPROBITY server¹⁴. The data collection andrefinement statistics are summarized in Table S1.

PDB Accession Numbers

Atomic coordinates of the present structures together with theexperimental structure factor amplitudes will be deposited in the RCSBProtein Data Bank.

TABLE S1 Data calculations and refinement statistics GCPII/ARM-P2GCPII/ARM-P4 GCPII/ARM-P8 GCPII/ARM-M4 PDB code TBD TBD TBD TBD DataCollection Statistics Wavelength ({acute over (Å)}) 1.0000 1.0000 1.00001.0000 Temperature (K) 100 Space group I222 Unit-cell parameters: a =101.5; a = 101.7; a = 101.8; a = 101.5; a, b, c ({acute over (Å)}) b =130.0; b = 130.0 b = 130.0; b = 130.0; c = 158.6 c = 159.0 c = 158.8 c =159.2 Resolution limits ({acute over (Å)}) 30.0-1.69 30.0-1.59 30.0-1.5930.0-1.78 (1.75-1.69)* (1.65-1.59)* (1.63-1.59)* (1.84-1.78)* Number ofunique 114,649 137,271 137,748 100,565 reflections (9,759) (11,088)(10,972) (9,717) Redundancy 5.8 (2.5) 7.0 (5.0) 6.6 (3.8) 7.1 (5.6)Completeness (%) 97.8 (84.1) 97.6 (79.9) 96.9 (77.9) 99.7 (97.3) I/σ(I)18.4 (2.1) 27.8 (2.0) 15.4 (2.6) 21.3 (2.5) R_(merge) 0.086 (0.492)0.058 (0.501) 0.078 (0.438) 0.086 (0.520) Refinement StatisticsResolution limits ({acute over (Å)}) 30.0-1.69 30.0-1.59 30.0-1.5920.0-1.78 (1.73-1.69)* (1.63-1.59)* (1.63-1.59)* (1.82-1.78)* Totalnumber of 112,878 (6,994) 135,823 (7,887) 135,631 (7,827) 99,006 (6,972)reflections Number of reflections 111,178 (6,872) 134,450 (7,815)133,594 (7,726) 97,519 (6,871) in working set Number of 1,700 (122)1,373 (72) 2,037 (101) 1,487 (101) reflections in test set R factor 16.0(23.6) 16.8 (25.3) 16.1 (24.6) 15.7 (26.6) Free-R 18.5 (29.3) 19.1(33.0) 18.3 (28.7) 18.5 (29.1) Total number of non- 6,491 6,618 6,6876,546 H atoms Number of inhibitor 92^(#) 52 128^(#) 41 atoms Number ofions 4 4 4 4 Number of water 505 612 581 563 molecules Average B factor({acute over (Å)}²) Protein atoms 28.0 25.9 24.5 18.7 Water molecules38.4 36.3 37.4 27.4 Ligand atoms 40.3 48.5 51.8 48.8 r.m.s.d. Bondlengths ({acute over (Å)}) 0.021 0.018 0.017 0.021 Bond angles (°) 1.851.71 1.69 1.72 Planarity ({acute over (Å)}) 0.011 0.010 0.011 0.010Chiral centers ({acute over (Å)}³) 0.14 0.13 0.12 0.14 Ramachandran plot(%)** Most favored 97.7 97.7 97.7 97.8 Allowed 2.3 2.3 2.3 2.2Disallowed 0 0 0 0 Missing residues 44-54; 654-655 44-54; 654-655 44-54;654-655 44-54; 654-655 *Values in parentheses correspond to the highestresolution shells **Calculated with MOLPROBITY¹⁴ ^(#)inhibitor modeledin two conformationsComputational StudiesQuantum Chemical Computations

Models of substituted methyl-amino-phenyls were constructed using thesoftware Maestro.¹⁵ All calculations were carried out using the Jaguarsuite of electronic structure programs.¹⁶ Geometry optimization wasperformed using Density functional theory with a 6-41G*+basis set andthe hybrid B3LYP functional.¹⁷

Molecular Dynamics Simulations

The crystal structure of ARM-P2-DNP in complex with PSMA (695 residues)was used to setup all the protein-ligand complexes. MeO-P0, ARM-P0,ARM-P2, ARM-P4 and ARM-P8 were modeled in the same protein structure onthe basis of available experimental data. The LigPrep module of thesoftware Maestro was used to add missing hydrogen atoms, choose theprotonation state of protein side chains, and minimize the energy of theprotein-ligand complex.¹⁸ The 2005 update of the OPLS force field wasused throughout.¹⁹ The resulting structure was then embedded in atriclinic box of circa 13300 TIP3P water molecules,²⁰ the dimension ofthe box was circa 96×87×94 Å. The net charge of the system wasneutralized by addition of one sodium ion to the solvent box. The totalnumber of atoms was circa 53,000 atoms. The simulations were performedwith the Desmond molecular dynamics package²¹. All bond lengths tohydrogen atoms were constrained using MM-SHAKE.²² Van der Waals andshort range electrostatic interactions were cut off at 9 Å. Long rangeelectrostatic interactions were computed using the particle mesh Ewaldmethod using a 32×32×32 grid with σ=2.18 Å and fifth-order B-splines forinterpolation.²³ A RESPA integrator was used with a time-step of 2 fs,and the long range electrostatic interactions were computed every 6fs.²⁴ Each system was initially energy minimized with steepest decentand then subjected to the following equilibration protocol: 12 ps ofdynamics at 10 K in the NVT ensemble (Berendsen thermostat)²⁵ andharmonic restraints (50 kcal/mol/A²) on the solutes heavy atoms,followed by 12 ps in the NPT ensemble (Berendsen thermostat andbarostat) at 10 K and retaining harmonic restraints on the solutes heavyatoms, followed by 24 ps in the NPT ensemble (Berendsen thermostat andbarostat) at 300 K and retaining harmonic restraints on the solutesheavy atoms, followed by 24 ps in the NPT ensemble (Berendsen thermostatand barostat) at 300 K without harmonic restraints on the solutes heavyatoms, followed by 100 ps of dynamics at 300 K in the NPT ensemble(Martyna-Tobias-Klein barostat and Nose-Hoover thermostat).^(26,27) Theproduction simulations were run for 50 nanoseconds in the NPT ensemble(300 K, 1 bar, Martyna-Tobias-Klein barostat and Nose-Hooverthermostat). Coordinates were saved every 10 ps and analyzed using thesoftware Visual Molecular Dynamics.²⁸

Results and Discussion

Dependence of Linker Length on Binding Affinity

TABLE 1 Linker length dependence on PSMA inhibitory potency.

Compound X n IC₅₀ (nM)^(b) K_(i) (nM)^(c) 1, ARM-P0 DNP^(a) 0 1.76 ±0.41 0.078 ± 0.018 2, ARM-P1 DNP 1 1.05 ± 0.11 0.047 ± 0.005 3, ARM-P2DNP 2 0.54 ± 0.18 0.024 ± 0.008 4, ARM-P4 DNP 4 0.46 ± 0.18 0.020 ±0.008 5, ARM-P6 DNP 5 2.29 ± 0.50 0.101 ± 0.027 6, ARM-P8 DNP 8 3.29 ±1.14 0.145 ± 0.050 7, ARM-P12 DNP 12 37.3 ± 15.2 1.65 ± 0.72 8, MeO-P0OMe 0 30.5 ± 12.1 1.35 ± 0.54 9, MeO-P2 OMe 2 40.8 ± 9.4  1.81 ± 0.4210, MeO-P4 OMe 4 30.2 ± 14.4 1.34 ± 0.64 11, MeO-P8 OMe 8 131.0 ± 57.6 5.79 ± 2.54 12, MeO-P12 OMe 12 165.2 ± 58.9  7.30 ± 2.60

^(b)IC₅₀ values represent the mean of triplicate experiments. ^(c)K_(i)values were calculated from IC₅₀ and K_(m) values using theCheng-Prusoff equation as described in the supporting information.

To evaluate in detail the effect of linker length on PSMA bindingaffinity, we prepared various derivatives of ARM-P (Table 1, 1-12).These compounds consist of glutamate ureas linked to DNP or methoxygroups by oxyethylene moieties of varying lengths. They are named ARM-Pxand MeO-Px, respectively, wherein “x” corresponds to the number ofoxyethylene units in the linker, Evaluation of these compounds for theirability to inhibit PSMA activity proved quite revealing. In all cases,ARM-P derivatives were found to possess Ki values lower in magnitudethan their counterparts lacking DNP (compounds I-7 versus 8-12). In somecases, the affinity difference was up to two orders of magnitude(compound 3 versus 9). This result indicated to us that perhaps the DNPfunction itself might be playing a role in binding PSMA. Such ahydrophobic interaction involving an aromatic ring and PSMA was notcompletely unexpected given the proximity of the glutamate-urea bindingsite to a known hydrophobic pocket in PSMA.^(17,18) Indeed, inhibitorscontaining hydrophobic functionality distal to the glutamic acid moietyhave exhibited high potency against PSMA.^(12,19,20)

A model involving binding of the DNP moiety to the hydrophobic pocketadjacent to the S1 site did not explain the decrease in affinity betweenARM-P2 and derivatives with shorter oxyethylene linkers (i.e., ARM-P0and ARM-P1). Indeed, one would expect ARM-P0 and ARM-P1 to exhibitenhanced potency versus ARM-P2 because of the close proximity of theaccessory hydrophobic pocket to the P1 glutamate binding cavity. Theopposite trend suggested perhaps the presence of an alternativehydrophobic binding site, situated at a substantial distance away fromthis cavity. This hypothesis is supported by observations in relatedsystems in which bifunctional ligands bind proteins at two remote sites.In such systems, an ideal linker length between binding poles isrequired for maximum affinity; linkers that are too short to accesssecondary binding sites experience suboptimal enthalpic benefit frombivalent binding, while linkers that are too long experience highentropic costs upon bivalent binding.²¹⁻²³

Notably, compounds within the MeO-P series (8-12) containing relativelyshort linkers all bind PSMA with comparable affinity. The presence oflinkers consisting of 8 oxyethylene groups or longer appears to inhibitcompound binding, a trend that can be explained on steric grounds.²⁴ Theincreased sensitivity of ARM-P derivatives to changes in linker lengthversus MeO-P compounds suggests that factors other than simple stericbulk are operating for the ARM-Ps.

Structure—Activity Studies: Effect of Varying Aromatic Groups on BindingAffinity

TABLE 2 Dependence of K_(i) on substituents and electronics of aromaticring.

Com- E_(HOMO) pound X (eV)^(a) IC₅₀ (nM)^(b) K_(i) (nM)^(c) 3, DNP−0.251 0.54 ± 0.18 0.024 ± 0.008 ARM-P2 13 o-NO₂-Ph −0.228 1.78 ± 0.150.078 ± 0.007 14 p-NO₂-Ph −0.231 1.36 ± 0.18 0.060 ± 0.008 15 Ph −0.20116.6 ± 6.3  0.73 ± 0.28 16 p-MeO-Ph −0.181 21.9 ± 9.9  0.97 ± 0.44 17Cyclohexyl N/A 342.3 ± 170.5 15.1 ± 7.5  ^(a)E_(HOMO) of the aryl ring(X) was calculated using Density Functional Theory, and reported inelectron-volts. The hybrid functional B3LYP with a 6-31G*+ basis set wasused. ^(b)IC₅₀ values represent the mean of triplicate experiments.^(c)K_(i) values were calculated using IC₅₀ and K_(m) values via theCheng-Prusoff equation as outlined in the supporting information. AK_(m) value of 925 nM was using in these calculations.

To test further our model for bidentate binding, we set out to probe theimpact of the phenyl ring substituent on inhibitor potency. We thereforesynthesized analogues of ARM-P2 replacing the DNP moiety with a range ofelectronically distinct aromatic species (3, 13-17, Table 2). As shown,these analogues included nitrophenyl (ortho and para to the linker),p-methoxyphenyl, phenyl, and cyclohexyl derivatives. Consistent with thehypothesis for multisite interaction, profound changes in affinity wereobserved in this series. Interestingly, the parentdinitrophenyl-containing compound (ARM-P2) possessed the highest potencyof all the analogues tested (Ki=24 pM), and removal of nitro groups ledto three-fold decreases in affinity in the p-nitrophenyl (13) ando-nitrophenyl (14) analogues (Ki=60 and 78 pM, respectively). Thesimilarities between these analogues suggests that inhibitor potency isdictated by electronic rather than steric effects. Phenyl (15) andmethoxyphenyl (16) analogues proved an additional order of magnitudeless potent than mononitrated derivatives (Ki=730 and 970 pM,respectively), and the cyclohexyl-substituted derivative (17) proved yetanother order of magnitude worse than the least potent aryl compounds(Ki=15.1 nM). This may result from the enhanced steric bulk of thecyclohexyl substituent versus planar arenes.

To quantify electronic effects in this system, we performed densityfunctional theory (DFT) calculations to relate the electron density ofthe aromatic ring to PSMA inhibitory potency.₂₅ For substituted arenesthis can be conveniently quantified by calculating the arene HOMOenergy. An excellent correlation was observed between the HOMO energiesof aromatic substituents and experimentally determined K_(i) values(FIG. 15). Electron poor aromatic rings are expected to experiencestrong π-stacking interactions with electron-rich arenes,^(26,27)suggesting perhaps that such interactions may be dominant in dictatingbinding affinity in this system. These results are strongly indicativeof multisite binding in the ARM-P series, and led us to test thishypothesis further using X-ray crystallography.

Crystallographic Studies

Initial refinement and analysis. Crystal structures were determined forPSMA in complex with ARM-P ligands containing 2, 4, and 8 oxyethyleneunits in the linker region (3, 4, and 6) and with MeO-P4 (10), whichlacks the DNP moiety, and were refined at the resolution of 1.69 Å, 1.59Å, 1.59 Å, and 1.78 Å, respectively. Individual compounds were fit intothe positive peaks on the difference F_(o)-Fc electron density map inthe final stages of refinement. For all four inhibitors, clearinterpretable densities were observed for the C-terminal partencompassing the P1′ glutarate, the urea linkage, the lysine linker andthe triazole ring. Although density corresponding to the DNP phenyl ringis defined in all ARM-P complexes, density corresponding to the nitrogroups is absent suggesting that the DNP moiety is present in at leasttwo different conformations. Also, electron density peaks correspondingto the poly-oxyethylene linker were absent from all complexes,consistent with a lack of intermolecular contacts between this flexibleelement and the protein.

Structures of ARM-P2, ARM-P4, and ARM-P8 in complex with PSMA aredepicted in FIG. 16. Despite the attachment of large oxyethylenelinkers, the glutamate urea portions of all inhibitors interact with theprotein active site in a fashion reminiscent of previously reportedcomplexes with urea12,13,17 and phosphonate28 inhibitors, and thesubstrate N-acetyl-aspartyl-glutamate (NAAG).29 In all structures,positioning of the P1′ glutarate is enforced by H-bonds (indicated asdashed lines) with Arg210, Asn257, Tyr552, Lys699, Tyr700, andactive-site water molecules, and hydrophobic interactions with the sidechains of Phe209 and Leu428. The ureido nitrogen atoms serve as H-bonddonors in interactions with Glu424 and the Gly518 main chain carbonyl,and the carbonyl oxygen makes contacts with both the catalytic zinc atomand Tyr552, and His553. The P1 α-carboxylate in all inhibitorsstructurally overlaps with the equivalent groups of previously reportedcomplexes, and is held in place by interactions with an arginine-richpatch (Arg463, Arg534, Arg536) along with H-bonding contacts to Asn519,the Ser517 main-chain carbonyl, and water molecules,^(17,18)

Discovery of an arene-binding cleft. A key site of interaction betweenPSMA and all ARM-P derivatives is the triazole ring, which was observedto pack against the side chains of Tyr552 and Tyr700 in all complexes(FIG. 16). The steric hindrance caused by the oxyethylene linkeremanating from the triazole ring prevents closure of the enzyme'sentrance lid (amino acids Trp541-Gly548), as observed for PSMA complexeswith smaller ligands.¹⁸ A key consequence of the entrance lid's openconformation is the revelation of a previously unreported binding cleftfor the DNP ring (FIG. 17).¹⁸

The arene-binding region, formed from the indole group of Trp541 and theguanidinium group of Arg511 holds the DNP ring in close contact withthese groups at distances of 3.1 Å and 3.9 Å, respectively. The bottomof the cleft is lined by the Arg463 side chain. Positioning of thephenyl ring creates a plane virtually parallel to both indole andguanidinium functionalities, suggesting that simultaneous π-cation(DNP-Arg511) and π-stacking (DNP-Trp541) interactions may bothcontribute to inhibitor binding._(31,32) Critically, the arene-bindingregion is only revealed upon opening of the entrance lid (FIG. 17B);closure of the entrance lid, as in the overlaid complex between PSMA andthe small urea-based inhibitor DCIBzL,₃₀ would lead to significantsteric overlap with the triazole moiety as well as closure of thearene-binding site (FIG. 17C). Thus, the protein is capable of adoptingtwo separate conformations, each suited to accommodate high-affinitybinding interactions with distinct classes of glutamate-urea inhibitors.

A key structural feature was observed in the MeO-P4 complex (FIG. 18).Here, unlike in the ARMP complexes, Trp541 exists in two distinctconformations. The non-stacking conformation is rotated approximately 4Å from what is seen in ARM-P complexes, and blocks the arene-bindinggroove. The conformational flexibility exhibited by Trp541 in thePSMA/MeO-P4 complex suggests that when present, the dinitroarenestabilizes the side chain indole moiety via π-stacking, as implied bythe ARMP structures depicted above. Taken together, these data providestrong support for a model in which ARM-Ps bind PSMA throughinteractions at both the enzyme active site and at a newly reportedarenebinding cleft. Notably, the complex between PSMA and MPE,₃₃ amethotrexate-derived phosphonate, was also shown to possess an openentrance lid like the complexes disclosed herein.¹⁸ It was concludedfrom the PSMA/MPE complex that the protein's ability to adopt an openconformation serves to enable its binding to relatively largesubstrates, such as folyl-poly-γ-glutamates. One might imagine that therevelation of an arene-binding site upon opening of the entrance lidmight serve to enhance affinity for these arene-containing enzymesubstrates. Interestingly, however, the pendant pteroyl ring in the MTEcomplex was not observed to interact with the PSMA arene-binding cleft,perhaps due to its relatively short linkage to the zinc-bindingphosphonate region. The observations reported herein suggest thatperhaps larger natural poly-γ-glutamate substrates are able to make useof the arene-binding site, however further studies are necessary to testthis possibility.

Molecular Dynamics (MD) Simulations

To clarify the nature of the protein-ligand interactions in the ARM-Pcomplexes, explicit solvent molecular dynamics (MD) simulations werecarried out using crystallographic data for PSMA complexes with ARM-P0,ARMP-P2, ARM-P4, ARM-P8 and MeO-P0. Each protein-ligand complex wasmodeled with the OPLS-AA force field,34 embedded in a triclinic box ofTIP3P water molecules.35 Dynamics were simulated for 50 ns using theDesmond software package.³⁶ These simulations revealed a number ofnoteworthy features (see Supporting Information for video files for allsimulations). Although the PSMA active site and glutamate urea moietiesare fairly rigid throughout the timescale of MD simulations, distalprotein-ligand interactions exhibit highly dynamic behavior. Forexample, the simulation of the MeO-P0-PSMA complex revealed that thearene-binding site is unstable in the absence of DNP; Trp541 tends torotate toward Arg511, thus obscuring the arenebinding site (FIG. 19,panels a-c). This observation directly correlates with the disorder inTrp541 observed in the MeO-P4-PSMA crystal structure (FIG. 16).Furthermore, the PEG moieties in all complexes are highly dynamic and donot seem to form specific interactions with PSMA, suggesting that thesemake minimal enthalpic contributions to binding affinity. Theseobservations also explain the absence of electron density correspondingto linker regions in all crystal structures.

By far the most stable intermolecular contact in the arene-binding sitein ARM-P-PSMA complexes is the stacking interaction between DNP andTrp541. For all ARMs, the DNP moieties participate in face-to-faceinteractions with Trp541 side chain indole moieties for significant timeperiods throughout MD simulations. Simulations of the ARM-P0-PSMAcomplex revealed a remarkable level of flexibility in the triazole-alkylregion, which enables π-stacking contacts in the arene-binding site toremain intact even in the absence of an oxyethylene linker (FIG. 19,panels d-f). When stacked with the Trp541 side chain indole, the DNPring is observed to rotate in-plane, supporting the hypothesis that thelack of well defined electron density corresponding to nitro groups incrystal structures is due to the presence of multiple areneconformations. However, in all ARM-P complexes, the nitro groups in theDNP ring are frequently observed pointing toward the Arg463 side chainguanidinium group, suggesting possible hydrogen bonding or electrostaticinteractions between these groups. Furthermore, althoughcrystallographic data support a role for π-cation interactions withArg511 in the arene-binding site, this residue is highly disordered inMD simulations, and does not form long-lived contacts with the ligand.This observation is consistent with the data presented in Table 2 andFIG. 15, which suggest that cation-π interactions play a relativelyminor role versus π-stacking interactions in stabilizing these systems.Notably, during the course of MD simulations for both ARM-P2 (panelsg-i) and ARM-P8 (panels m-o), the DNP ring dissociates from thearene-binding cleft, whereas this interaction remains intact in theARM-P4 simulation (panels j-l). Taken together, these data suggest thatthe DNP-Trp541 interactions are relatively weak. Interestingly, thecontact with Trp541 reforms rapidly during the simulations of ARM-P2,but not ARM-P8; this likely reflects both the high entropic penaltyassociated with bivalent binding in ARM-P8 as well as the tendency forthe molecule's lengthy PEG linker to occupy the arene-binding site, thuspreventing the DNP group's return to Trp541. From a functionalstandpoint, the propensity of ARM-P8 to disengage from the PSMAarene-binding site enables it to form ternary complexes with prostatecancer cells and antibodies, which is critical to its cytotoxicactivity.³ However, this functionality comes at the expense of PSMAbinding affinity. This model suggests the possibility of ultrahigh-affinity ARM-P analogues capable of interacting simultaneously withthe PSMA arene-binding site and anti-DNP antibodies.

CONCLUSION

In the present application we have detailed the discovery of anarene-binding site on pro state-specific membrane antigen (PSMA), whichgives rise to unusually high affinity binding interactions with designedbifunctional antibody-recruiting small molecules (ARMs). The conclusionspresented herein are supported by extensive crystallographic,biochemical, and computational data, which, taken together, stronglysuggests a model in which bidentate binding of ARM-Ps to PSMA leads tosubstantial increases in inhibitor potency. The serendipitous nature ofthe discovery reported herein along with the relative simplicity of thePSMA arene-binding site—which consists merely of three amino acids onlyone of which (Trp541) is responsible for affinity enhancement—suggestthat low-affinity binding sites for arenes could be quite prevalentamong proteins. Along these lines, it is well-documented that a largeproportion of circulating immunoglobulin possess high-affinity bindingactivity against nitroarene ligands,38 and between 1 and 10% of myelomaproteins bind nitrophenyl ligands.³⁹ The possibility that such bindingsites arise from conserved folds within immunoglobulin domains has beensuggested,⁴⁰ however, this trend may also result from the uniqueimmunogenicity of nitroarenes,^(41,42) a property that has also beenattributed to their propensity to form hydrophobic contacts withproteins.₄₁ In either case, although structural data existsdemonstrating the unique propensity of nitroarenes to engage inπ-stacking interactions with aromatic amino acid side chains,_(43,44)the proteomic prevalence of nitroarene-binding motifs has not beensystematically explored. The widespread existence of such binding sitescould enable facile optimization of small molecule ligands for proteinsidentified through high-throughput screening, and could find readyutility in fragment-based approaches to inhibitor design.⁴⁵

Although underexplored, strategies that utilize small molecules toenhance recognition of pathogens by the human immune system promise toleverage the strengths of both antibody- and small-moleculebasedtherapeutic approaches. The results reported herein suggest thepossibility for improving such technologies for treating prostatecancer. For example, ultra-high-affinity ARM-Ps could be constructed byexploiting the presence of the arene-binding site in PSMA and convertingthe highly flexible first generation ARM-Ps into more rigid scaffolds.More broadly, the high-level expression of PSMA (GCPII) on prostatecancer cell surfaces and on tumor neovasculature,⁴⁶ as well as itsputative role in the pathophysiology of schizophrenia,⁴⁷ have renderedit an extremely useful and popular target for inhibitor design. Theresults presented herein therefore could substantially impact thedevelopment of effective diagnostic and therapeutic approaches forpatients suffering from cancer and other diseases.

The complete disclosure of all patents, patent applications, andpublications, and electronically available material (including, forinstance, nucleotide sequence submissions in, e.g., GenBank and RefSeq,and amino acid sequence submissions in, e.g., SwissProt, PIR, PRF, PDB,and translations from annotated coding regions in GenBank and RefSeq)cited herein are incorporated by reference. Any inconsistency betweenthe material incorporated by reference and the material set for in thespecification as originally filed shall be resolved in favor of thespecification as originally filed. The foregoing detailed descriptionand examples have been given for clarity of understanding only. Nounnecessary limitations are to be understood therefrom. The invention isnot limited to the exact details shown and described, for variationsobvious to one skilled in the art will be included within the inventiondefined by the following claims.

All headings are for the convenience of the reader and should not beused to limit the meaning of the text that follows the heading, unlessso specified.

The invention claimed is:
 1. A method of treating prostate cancer in apatient in need thereof comprising administering to said patient aneffective amount of a compound according to the chemical structure:

wherein A is an antibody binding moiety according to the chemicalformula:

Y′ is H or NO₂; X is O, CH₂, NR¹, S(O), S(O)₂, —S(O)₂O, —OS(O)₂, orOS(O)₂O; R¹ is H, a C₁-C₃ alkyl group, or a —C(O)(C₁-C₃) group; X′ isCH₂, O, N—R^(1′) or S; R^(1′) is H or C₁-C₃ alkyl; Z is a bond, amonosaccharide, disaccharide, oligosaccharide, glycoprotein orglycolipid; X^(b) is a bond, O, CH₂, NR¹ or S; X″ is O, CH₂, NR¹; R¹ isH, a C₁-C₃ alkyl group or a —C(O)(C₁-C₃) group; n is 1 or 2; n¹ is 1; Bis a cell binding moiety according to the chemical formula:

Where X₁ and X₂ are each independently CH₂, O, NH or S; X₃ is O, CH₂,NR¹, S(O), S(O)₂, —S(O)₂O, —OS(O)₂, or OS(O)₂O; R¹ is H, a C₁-C₃ alkylgroup, or a —C(O)(C₁-C₃) group; k is an integer from 0 to 20; L is alinker according to the chemical formula:

Or a polypropylene glycol or polypropylene-co-polyethylene glycol linkerhaving between 1 and 100 glycol units; Where R_(a) is H, C₁-C₃ alkyl oralkanol or forms a proline side chain with R³; R³ forms a proline sidechain with R_(a) or is a side chain derived from an amino acid whereinsaid amino acid is selected from the group consisting of alanine,arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid,glycine, histidine, isoleucine, leucine, lysine, methionine,phenylalanine, serine, threonine, tryptophan, tyrosine and valine; and mis an integer from 1 to 45, or L is a linker according to the chemicalformula:

Where Z and Z′ are each independently a bond, —(CH₂)_(i)—O,—(CH₂)_(i)—S, —(CH₂)_(i)—N—R,

wherein said —(CH₂)_(i) group, if present in Z or Z′, is bonded to [CON]if present, antibody binding terminus (ABT) or cell binding terminus(CBT); Each R is independently H, or a C₁-C₃ alkyl or alkanol group;Each R² is independently H or a C₁-C₃ alkyl group; Each Y isindependently a bond, O, S or N—R; Each i is independently 0 to 100; Dis

or a bond, with the proviso that Z, Z′ and D are not each simultaneouslybonds; j is 1 to 100; m′ is 1 to 100; n′ is 1 to 100; and X¹ is O, S orN—R, R is as defined above; and [CON] is a bond or a moiety according tothe chemical structure:

Where X² is O, S, NR⁴, S(O), S(O)₂, —S(O)₂O, —OS(O)₂, or OS(O)₂O; X³ isNR⁴, O or S; and R⁴ is H, a C₁-C₃ alkyl or alkanol group, or a—C(O)(C₁-C₃) group; or a pharmaceutically acceptable salt thereof. 2.The method according to claim 1 wherein A is

X is O or NH; Y′ is H; X′ is O; and Z is a bond, a monosaccharide or adisaccharide, or a pharmaceutically acceptable salt thereof.
 3. Themethod according to claim 1 wherein A is

where X is O or NR¹; and R¹ is H, a C₁-C₃ alkyl group, or a —C(O)(C₁-C₃)group, or a pharmaceutically acceptable salt thereof.
 4. The methodaccording to claim 1 wherein said linker is a group according to thechemical formula:

Where R_(a) is H, C₁-C₃ alkyl or alkanol or forms a proline side chainwith R³; R³ forms a proline side chain with R_(a) or is a side chainderived from an amino acid wherein said amino acid is selected from thegroup consisting of alanine, arginine, asparagine, aspartic acid,cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine,leucine, lysine, methionine, phenylalanine, serine, threonine,tryptophan, tyrosine and valine; and m is an integer from 1 to 45, or mis an integer from 1 to
 10. 5. The method according to claim 1 wherein[CON] is, a

group or a

group where X² is a NR⁴ group and R⁴ is H or a C₁-C₃ alkyl group.
 6. Themethod according to claim 1 wherein said linker is a group according tothe formula:

wherein m is an integer from 1 to
 15. 7. The method according to claim 1wherein A is

X is O or NH; L is a

group; where m is an integer from 5 to 15; and [CON] is attached to A orB through linker L.
 8. The method according to claim 1 wherein saidLinker group L is based upon a polyethylene glycol having between 1 and15 glycol units.
 9. The method according to claim 1 wherein said Linkergroup L is based upon a polyethylene glycol having between 6 and 10glycol units.
 10. The method according to claim 1 wherein A is

B is a

group, where k is an integer from 1 to 6; L is a linker based uponpolyethylene glycol having from 1 to 15 ethylene glycol units; and [CON]is a

group, or a pharmaceutically acceptable salt thereof.
 11. A method oftreating prostate cancer in a patient in need thereof comprisingadministering to said patient an effective amount of a compoundaccording to the chemical structure:

where n is 1 to 15, or a pharmaceutically acceptable salt thereof.
 12. Amethod of treating prostate cancer in a patient in need thereofcomprising administering to said patient an effective amount of acompound according to the chemical structure:

where n is 0 to 8, or a pharmaceutically acceptable salt thereof. 13.The method according to claim 1 wherein said prostate cancer ismetastatic prostate cancer.
 14. The method according to claim 11 whereinsaid compound is co-administered with an anti-cancer effective amount ofan additional anticancer agent.
 15. The method according to claim 12wherein said compound is co-administered with an anti-cancer effectiveamount of an additional anticancer agent.
 16. The method according toclaim 13 wherein said compound is co-administered with an anti-cancereffective amount of an additional anticancer agent.
 17. The methodaccording to claim 14 wherein said additional anticancer agent is anantimetabolite, an inhibitor of topoisomerase I and II, an alkylatingagent, a microtubule inhibitor or mixtures thereof.
 18. The methodaccording to claim 14 wherein said additional anticancer agent isaldesleukin; aemtuzumab; alitretinoin; allopurinol; altretamine;amifostine; anastrozole; arsenic trioxide; aparaginase; BacillusCalmette-Guerin Live; bexarotene capsules; bexarotene gel; bleomycin;busulfan intravenous; busulfan oral; calusterone; capecitabine;carboplatin; carmustine; carmustine with polifeprosan 20 implant;celecoxib; chlorambucil; cisplatin; cladribine; cyclophosphamide;cytarabine; cytarabine liposomal; dacarbazine; dactinomycin; actinomycinD; dabepoetin alfa; daunorubicin liposomal; daunorubicin, daunomycin;denileukin diftitox, dexrazoxane; docetaxel; doxorubicin; doxorubicinliposomal; domostanolone propionate; eliott's B solution; epirubicin;eoetin alfa estramustine; etoposide phosphate; etoposide (VP-16);exemestane; flgrastim; floxuridine; fludarabine; fluorouracil (5-FU);fulvestrant; gemtuzumab ozogamicin; goserelin acetate; hydroxyurea;Ibritumomab Tiuxetan; idarubicin; ifosfamide; imatinib mesylate;Interferon alfa-2a; Interferon alfa-2b; irinotecan; letrozole;leucovorin; levamisole; lomustine (CCNU); meclorethamine (nitrogenmustard); megestrol acetate; melphalan (L-PAM); mercaptopurine (6-MP);mesna; methotrexate; methoxsalen; mitomycin C; mitotane; mitoxantrone;nandrolone phenpropionate; nofetumomab; L-O-dideoxy cytidine; orelvekin;oxaliplatin; paclitaxel; pamidronate; pegademase; Pegaspargase;Pegfilgrastim; pentostatin; pipobroman; plicamycin; mithramycin;porfimer sodium; procarbazine; quinacrine; Rasburicase; Rituximab;Sargramostim; streptozocin; telbivudine (LDT); talc; tamoxifen;temozolomide; teniposide (VM-26); testolactone; thioguanine (6-TG);thiotepa; topotecan; toremifene; Tositumomab; Trastuzumab; tretinoin(ATRA); Uracil Mustard; valrubicin; valtorcitabine (monoval LDC);vinblastine; vinorelbine; zoledronate; and mixtures thereof.
 19. Themethod according to claim 1 wherein said compound is co-administeredwith at least one antiandrogen compound.
 20. The method according toclaim 1 wherein said compound is co-administered with at least one GNRhmodulator.
 21. The method according to claim 1 wherein said compound isco-administered with at least one agent selected from the groupconsisting of eulexin, flutamide, bicalutamide, nilutamide, cyproteroneacetate, ketoconazole, aminoglutethimide, abarelix, leuprolide, lupron,nilandron, nilutamide, zoladex, goserelin, triptorelin, buserelin,abiraterone acetate, sorafenib and mixtures thereof.
 22. The methodaccording to claim 1 wherein said compound is administered in parenteraldosage form.
 23. The method according to claim 11 wherein said compoundis administered in parenteral dosage form.
 24. The method according toclaim 12 wherein said compound is administered in parenteral dosageform.
 25. A method of inhibiting metastasis of prostate cancer in apatient in need thereof comprising administering to said patient aneffective amount of a compound as set forth in claim
 1. 26. A method ofinhibiting metastasis of prostate cancer in a patient in need thereofcomprising administering to said patient an effective amount of acompound as set forth in claim
 11. 27. A method of inhibiting metastasisof prostate cancer in a patient in need thereof comprising administeringto said patient an effective amount of a compound as set forth in claim12.